120511-73-1 | Anastrozole

Packsize	Purity	Availability	Price	Discounted Price
100mg	99%	in stock	$30.00	$21.00
1g	99%	in stock	$66.00	$47.00
5g	99%	in stock	$226.00	$158.00
25g	99%	in stock	$1,028.00	$720.00

Description

• Catalog Number: AE18424
• Chemical Name: Anastrozole
• CAS Number: 120511-73-1
• Molecular Formula: C17H19N5
• Molecular Weight: 293.36625999999995
• MDL Number: MFCD00866298
• SMILES: N#CC(c1cc(cc(c1)C(C#N)(C)C)Cn1ncnc1)(C)C

Computed Properties

• Complexity: 456
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 4
• XLogP3: 2.1

Literature

• Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers.

  Toxicology and applied pharmacology 20180101

• Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20160101

• Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene.

  Journal of clinical research in pediatric endocrinology 20150901

• Rapid fluorescent detection of (anti)androgens with spiggin-gfp medaka.

  Environmental science & technology 20140916

• Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action.

  PloS one 20140101

• Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20131201

• Preventive therapy for breast cancer.

  Current oncology reports 20121201

• The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

  Lung cancer (Amsterdam, Netherlands) 20121201

• Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.

  Carcinogenesis 20121101

• Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

  Breast cancer research and treatment 20121101

• Soy products in the management of breast cancer.

  Current opinion in clinical nutrition and metabolic care 20121101

• Anastrozole and fulvestrant in metastatic breast cancer.

  The New England journal of medicine 20121025

• Anastrozole and fulvestrant in metastatic breast cancer.

  The New England journal of medicine 20121025

• Anastrozole and fulvestrant in metastatic breast cancer.

  The New England journal of medicine 20121025

• Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.

  Nature reviews. Clinical oncology 20121001

• The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

  The Journal of steroid biochemistry and molecular biology 20120901

• Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

  European journal of cancer (Oxford, England : 1990) 20120901

• Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.

  Journal of cancer research and clinical oncology 20120901

• Aromatase inhibitors and mood disturbances.

  Palliative & supportive care 20120901

• Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol.

  Steroids 20120901

• Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.

  Radiology 20120901

• Uncommon metastatic site from breast cancer.

  Vojnosanitetski pregled 20120901

• Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820

• Aromatase inhibition in obese women: how much is enough?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820

• Combination anastrozole and fulvestrant in metastatic breast cancer.

  The New England journal of medicine 20120802

• Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.

  Journal of receptor and signal transduction research 20120801

• Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).

  Current medical research and opinion 20120801

• Lipid profiles within the SABRE trial of anastrozole with and without risedronate.

  Breast cancer research and treatment 20120801

• Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.

  The Journal of surgical research 20120701

• Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study.

  Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 20120701

• Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

  Journal of bone and mineral metabolism 20120701

• Aromatase inhibitors and calcium absorption in early stage breast cancer.

  Breast cancer research and treatment 20120701

• In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.

  Drug metabolism and disposition: the biological fate of chemicals 20120701

• Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios.

  Fertility and sterility 20120701

• Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.

  Breast cancer research and treatment 20120701

• A priming role of local estrogen on exogenous estrogen-mediated synaptic plasticity and neuroprotection.

  Experimental & molecular medicine 20120630

• Whole-genome analysis informs breast cancer response to aromatase inhibition.

  Nature 20120621

• Spectral characterization of the binding and conformational changes of serum albumins upon interaction with an anticancer drug, anastrozole.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20120615

• FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

  Breast cancer research and treatment 20120601

• Combined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiency.

  European journal of endocrinology 20120601

• Polyendocrine treatment in estrogen receptor-positive breast cancer: a 'FACT' yet to be proven.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• Pharmacogenomics of third-generation aromatase inhibitors.

  Expert opinion on pharmacotherapy 20120601

• Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.

  Anticancer research 20120601

• Pathological complete response in younger and older breast cancer patients.

  Archives of medical science : AMS 20120509

• Sex differences in the effectiveness of treadmill training in enhancing axon regeneration in injured peripheral nerves.

  Developmental neurobiology 20120501

• Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).

  Breast cancer research and treatment 20120501

• Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats.

  American journal of physiology. Renal physiology 20120501

• Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.

  JPMA. The Journal of the Pakistan Medical Association 20120501

• Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.

  Bioorganic & medicinal chemistry 20120415

• Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.

  Annals of surgical oncology 20120401

• Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

  Breast cancer research and treatment 20120401

• Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.

  Breast cancer research and treatment 20120401

• Aromatase inhibitors in premenopausal breast cancer.

  The Lancet. Oncology 20120401

• Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

  The Lancet. Oncology 20120401

• Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men.

  Steroids 20120401

• Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2, OATP-2B1, OATP-3A1) in malignant and non-malignant human breast cells in vitro.

  Maturitas 20120401

• Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.

  Clinical chemistry 20120401

• Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.

  Bioorganic & medicinal chemistry 20120401

• CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

  Journal of the National Cancer Institute 20120321

• [The effect of diet induced obesity on testicular tissue and serum oxidative stress parameters].

  Actas urologicas espanolas 20120301

• Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.

  Cancer science 20120301

• Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association.

  The Journal of urology 20120301

• Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120301

• Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120301

• [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120301

• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  The New England journal of medicine 20120209

• Breast cancer: Anastrozole sets the STAGE for premenopausal women.

  Nature reviews. Clinical oncology 20120207

• Hydrophilic interaction chromatography-electrospray ionization tandem mass spectrometric analysis of anastrozole in human plasma and its application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20120201

• Acute testosterone deprivation reduces insulin sensitivity in men.

  Clinical endocrinology 20120201

• Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.

  Breast (Edinburgh, Scotland) 20120201

• Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.

  Breast (Edinburgh, Scotland) 20120201

• Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.

  Cancer prevention research (Philadelphia, Pa.) 20120201

• Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.

  Climacteric : the journal of the International Menopause Society 20120201

• International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency.

  The Journal of allergy and clinical immunology 20120201

• Human steroid biosynthesis for the oncologist.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20120201

• Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.

  Clinical therapeutics 20120201

• Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.

  Cancer 20120101

• Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice.

  Neurobiology of disease 20120101

• Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review.

  European journal of cancer care 20120101

• 5α-reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives.

  International journal of biological macromolecules 20120101

• Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.

  Endocrine journal 20120101

• Effect of simvastatin on the pharmacokinetics of anastrozole.

  Breast cancer research and treatment 20120101

• Clitoral metastasis from ductal breast cancer revealing metastases in multiple sites and review of the literature.

  Journal of lower genital tract disease 20120101

• Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).

  PloS one 20120101

• Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101

• Molecular bases and phenotypic determinants of aromatase excess syndrome.

  International journal of endocrinology 20120101

• Aromatase inhibitors for PCOS: a systematic review and meta-analysis.

  Human reproduction update 20120101

• Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.

  International journal of endocrinology 20120101

• Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.

  Clinical Medicine Insights. Oncology 20120101

• Innovative oral treatments of uterine leiomyoma.

  Obstetrics and gynecology international 20120101

• Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature.

  Case reports in medicine 20120101

• Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.

  Cancer management and research 20120101

• Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.

  Breast cancer research : BCR 20120101

• McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.

  Orphanet journal of rare diseases 20120101

• Carcinomatous pericarditis in 3 breast cancer patients with long-term survival.

  Case reports in oncology 20120101

• Ductal carcinoma in situ: what can we learn from clinical trials?

  International journal of surgical oncology 20120101

• Leiomyomatosis peritonealis disseminata associated with endometriosis and multiple uterus-like mass: report of two cases.

  Clinical medicine insights. Case reports 20120101

• Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.

  Frontiers in pharmacology 20120101

• Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.

  PloS one 20120101

• Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.

  The breast journal 20120101

• Partial benefit of anastrozole in the long-term treatment of precocious puberty in McCune-Albright syndrome.

  Journal of pediatric endocrinology & metabolism : JPEM 20120101

• Aromatase inhibition attenuates desflurane-induced preconditioning against acute myocardial infarction in male mouse heart in vivo.

  PloS one 20120101

• Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review.

  BMC medicine 20120101

• Determination and characterization of degradation products of anastrozole by LC-MS/MS and NMR spectroscopy.

  Journal of pharmaceutical and biomedical analysis 20111215

• Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111215

• Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

  Current drug targets 20111201

• Identifying potential adverse effects using the web: a new approach to medical hypothesis generation.

  Journal of biomedical informatics 20111201

• Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.

  Breast cancer research and treatment 20111201

• Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

  Cancer prevention research (Philadelphia, Pa.) 20111201

• Progress in endocrine approaches to the treatment and prevention of breast cancer.

  Maturitas 20111201

• An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.

  Advances in therapy 20111201

• [Role of medical treatment for symptomatic leiomyoma management in premenopausal women].

  Journal de gynecologie, obstetrique et biologie de la reproduction 20111201

• Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.

  Drug safety 20111201

• Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.

  Clinical journal of oncology nursing 20111201

• Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast.

  Journal of breast cancer 20111201

• Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in korean women with locally advanced breast cancer.

  Journal of breast cancer 20111201

• Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120

• The breast cancer chemoprevention debate.

  Journal of the National Cancer Institute 20111116

• Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

  Lancet (London, England) 20111112

• Embracing the complexity of comorbidity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110

• Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110

• Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110

• Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.

  Breast cancer research and treatment 20111101

• A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.

  Journal of alternative and complementary medicine (New York, N.Y.) 20111101

• 4-({(E)-[2-(But-3-en-1-yl)-1-(prop-2-en-1-yl)-4-sulfanyl-1H-imidazol-5-yl]methyl-idene}amino)-3-phenyl-1H-1,2,4-triazole-5(4H)-thione.

  Acta crystallographica. Section E, Structure reports online 20111101

• [Determination of 6 antiestrogens in fish tissues by ultra performance liquid chromatography-tandem mass spectrometry].

  Se pu = Chinese journal of chromatography 20111101

• Direct spectroscopic evidence for binding of anastrozole to the iron heme of human aromatase. Peering into the mechanism of aromatase inhibition.

  Chemical communications (Cambridge, England) 20111014

• A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

  Breast cancer research and treatment 20111001

• Breast cancer medications and vision: effects of treatments for early-stage disease.

  Current eye research 20111001

• Strategies for maximizing growth in puberty in children with short stature.

  Pediatric clinics of North America 20111001

• Grover disease (transient acantholytic dermatosis) induced by anastrozole.

  Cutis 20111001

• Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110915

• Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.

  Medical oncology (Northwood, London, England) 20110901

• Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.

  Psycho-oncology 20110901

• Inhibition of estradiol synthesis attenuates renal injury in male streptozotocin-induced diabetic rats.

  American journal of physiology. Renal physiology 20110901

• Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.

  Japanese journal of clinical oncology 20110901

• Update on adjuvant hormonal treatment of early breast cancer.

  Advances in therapy 20110901

• Management of patients with metastatic breast cancer.

  Advances in therapy 20110901

• Initialization of adjuvant hormonal treatment for breast cancer.

  Advances in therapy 20110901

• Contemporary issues in precocious puberty.

  Indian journal of endocrinology and metabolism 20110901

• Invasive lobular breast cancer presenting an unusual metastatic pattern in the form of peritoneal and rectal metastases: a case report.

  Journal of breast cancer 20110901

• 3-(4-Nitro-phen-yl)-1H-1,2,4-triazole-5(4H)-thione.

  Acta crystallographica. Section E, Structure reports online 20110901

• Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.

  ChemMedChem 20110801

• Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

  Endocrine-related cancer 20110801

• Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110801

• Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.

  Breast cancer research and treatment 20110801

• Five-day anastrozole group in infertility needs supplemental human chorionic gonadotropin.

  Fertility and sterility 20110801

• Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.

  Breast cancer research and treatment 20110801

• Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Fulvestrant revisited: efficacy and safety of the 500-mg dose.

  Clinical breast cancer 20110801

• Current role and safety profile of aromatase inhibitors in early breast cancer.

  Expert review of anticancer therapy 20110801

• Autophagy and endocrine resistance in breast cancer.

  Expert review of anticancer therapy 20110801

• Use of Oncotype DX in Women with Node-Positive Breast Cancer.

  PLoS currents 20110721

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• Molecular effects of oestrogen deprivation in breast cancer.

  Molecular and cellular endocrinology 20110704

• Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

  Breast cancer research and treatment 20110701

• Overview of adjuvant trials of aromatase inhibitors in early breast cancer.

  Steroids 20110701

• Binding features of steroidal and nonsteroidal inhibitors.

  Steroids 20110701

• Examination of the use of Exemestane in patients with metastatic breast cancer.

  Breast cancer (Tokyo, Japan) 20110701

• Association between breast cancer subtypes and response to neoadjuvant anastrozole.

  Steroids 20110701

• Predictive algorithms for adjuvant therapy: TransATAC.

  Steroids 20110701

• An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.

  Steroids 20110701

• Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

  The Lancet. Oncology 20110701

• Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

• [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110701

• Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610

• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

  British journal of cancer 20110607

• Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.

  American journal of clinical oncology 20110601

• The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study.

  Annals of surgical oncology 20110601

• An 'omics' approach to determine the mechanisms of acquired aromatase inhibitor resistance.

  Omics : a journal of integrative biology 20110601

• When to start an aromatase inhibitor: now or later?

  Journal of surgical oncology 20110601

• Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.

  Fertility and sterility 20110601

• Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors.

  European journal of medicinal chemistry 20110601

• Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.

  Clinical breast cancer 20110601

• Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.

  Hormones & cancer 20110601

• Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.

  Journal of breast cancer 20110601

• Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.

  British journal of cancer 20110510

• Synthesis of α-aryl nitriles through palladium-catalyzed decarboxylative coupling of cyanoacetate salts with aryl halides and triflates.

  Angewandte Chemie (International ed. in English) 20110502

• Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.

  Journal of cancer research and clinical oncology 20110501

• Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.

  Journal of cancer research and clinical oncology 20110501

• Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

• Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.

  Breast cancer research and treatment 20110501

• Drug safety evaluation of exemestane.

  Expert opinion on drug safety 20110501

• Preventive therapy for breast cancer: a consensus statement.

  The Lancet. Oncology 20110501

• Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20110501

• 7-(4-Chloro-benzyl-idene)-3-[(4-chloro-phen-oxy)meth-yl]-6-(4-nitro-thio-phen-2-yl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thia-diazine.

  Acta crystallographica. Section E, Structure reports online 20110501

• Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?

  Annals of the Royal College of Surgeons of England 20110501

• Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre.

  British journal of cancer 20110426

• An ultraperformance liquid chromatography-tandem mass spectrometry method for determination of anastrozole in human plasma and its application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20110401

• Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110401

• A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20110401

• Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study.

  Fertility and sterility 20110401

• Anastrozole single-dose protocol in women with oligo- or anovulatory infertility: results of a randomized phase II dose-response study.

  Fertility and sterility 20110401

• Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).

  Endocrine-related cancer 20110401

• A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110401

• Anastrozole versus clomiphene citrate: which is better for ovulation induction?

  Fertility and sterility 20110401

• Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.

  Journal of materials science. Materials in medicine 20110401

• Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.

  Anticancer research 20110401

• ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.

  PLoS genetics 20110401

• [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110401

• Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?

  British journal of cancer 20110329

• Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.

  Journal of medicinal chemistry 20110324

• Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial.

  British journal of cancer 20110315

• A case of ectopic breast cancer with a literature review.

  Surgical oncology 20110301

• The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• Does anastrozole affect bone resorption similarly in early and late postmenopausal women?

  Calcified tissue international 20110301

• 10-year analysis of the ATAC trial: wrong conclusion?

  The Lancet. Oncology 20110301

• [A case of possible retroperitoneal metastasis of breast cancer successfully treated with oral S-1 and cyclophosphamide therapy after TC therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• Eight-year follow-up of a girl with McCune-Albright syndrome.

  Journal of clinical research in pediatric endocrinology 20110301

• Depressogenic effects of medications: a review.

  Dialogues in clinical neuroscience 20110301

• [Aromatase inhibitors and arthralgia].

  Magyar onkologia 20110301

• A novel approach for long-term oral drug administration in animal research.

  Journal of neuroscience methods 20110215

• Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.

  Drugs 20110212

• Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making?

  Critical reviews in oncology/hematology 20110201

• Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia.

  Internal medicine journal 20110201

• Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.

  Breast cancer research and treatment 20110201

• Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study.

  Bone 20110201

• Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.

  Menopause (New York, N.Y.) 20110201

• Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110201

• Chemotherapy: Anastrozole superiority to tamoxifen for early breast cancer confirmed.

  Nature reviews. Clinical oncology 20110201

• Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.

  Anticancer research 20110201

• Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.

  British journal of cancer 20110104

• Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature.

  American journal of therapeutics 20110101

• Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW).

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110101

• Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.

  Breast cancer research and treatment 20110101

• Rheumatoid arthritis and aromatase inhibitors.

  Joint, bone, spine : revue du rhumatisme 20110101

• In vivo treatments with fulvestrant and anastrozole differentially affect gene expression in the rat efferent ductules.

  Biology of reproduction 20110101

• Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.

  Cancer chemotherapy and pharmacology 20110101

• Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.

  Breast cancer research and treatment 20110101

• Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?

  Journal of biomedicine & biotechnology 20110101

• Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.

  Breast cancer research : BCR 20110101

• Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.

  Anticancer research 20110101

• Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

  Breast cancer research : BCR 20110101

• Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training.

  Journal of aging research 20110101

• Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study.

  Hormone research in paediatrics 20110101

• Treatment options for polycystic ovary syndrome.

  International journal of women's health 20110101

• [A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110101

• Do aromatase inhibitors have adverse effects on cognitive function?

  Breast cancer research : BCR 20110101

• Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.

  BMC cancer 20110101

• Anastrozole-related acute hepatitis with autoimmune features: a case report.

  BMC gastroenterology 20110101

• Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.

  Breast cancer research : BCR 20110101

• Honey induces apoptosis in renal cell carcinoma.

  Pharmacognosy magazine 20110101

• Gynecomastia - evaluation and current treatment options.

  Therapeutics and clinical risk management 20110101

• Cerebellar degeneration as presenting symptom of recurrent endometrial stromal sarcoma with sex-cord elements.

  Case reports in neurology 20110101

• Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.

  Endocrine journal 20110101

• Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.

  OncoTargets and therapy 20110101

• Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations.

  International journal of pediatric endocrinology 20110101

• Interpreting clinical assays for histone deacetylase inhibitors.

  Cancer management and research 20110101

• Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

  Breast cancer research : BCR 20110101

• Malignancy-associated dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay.

  PloS one 20110101

• Anti-inflammatory and antinociceptive evaluation of newly synthesized 4-(substituted ethanoyl) amino-3-mercapto-5-(4-methoxy) phenyl-1,2,4-triazoles.

  Journal of pharmacy & bioallied sciences 20110101

• Extended letrozole regimen versus clomiphene citrate for superovulation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial.

  Reproductive biology and endocrinology : RB&E 20110101

• Aromatase inhibitors in stimulated IVF cycles.

  Reproductive biology and endocrinology : RB&E 20110101

• Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate.

  Reproductive biology and endocrinology : RB&E 20110101

• The emerging use of aromatase inhibitors for endometriosis treatment.

  Reproductive biology and endocrinology : RB&E 20110101

• Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial.

  Reproductive biology and endocrinology : RB&E 20110101

• Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review.

  Reproductive biology and endocrinology : RB&E 20110101

• Aromatase inhibitors in post-menopausal endometriosis.

  Reproductive biology and endocrinology : RB&E 20110101

• Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.

  Reproductive biology and endocrinology : RB&E 20110101

• Aromatase inhibitors in men: effects and therapeutic options.

  Reproductive biology and endocrinology : RB&E 20110101

• Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.

  PloS one 20110101

• Promising molecular targeted therapies in breast cancer.

  Indian journal of pharmacology 20110101

• Surviving metastatic breast cancer for 18 years: a case report and review of the literature.

  The breast journal 20110101

• Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of articledeveloping erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery.

  BMC cancer 20110101

• TP53 status and response to treatment in breast cancers.

  Journal of biomedicine & biotechnology 20110101

• Aromatase activity and bone loss in men.

  Journal of osteoporosis 20110101

• Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.

  Breast cancer research : BCR 20110101

• Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

  PloS one 20110101

• Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas.

  BMC cancer 20110101

• Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.

  Journal of experimental & clinical cancer research : CR 20110101

• Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.

  BMC cancer 20110101

• Managing the personal side of health: how patient expertise differs from the expertise of clinicians.

  Journal of medical Internet research 20110101

• Orbital metastases as first sign of metastatic spread in breast cancer: case report and review of the literature.

  Head & neck oncology 20110101

• Increased fracture rate in women with breast cancer: a review of the hidden risk.

  BMC cancer 20110101

• Choosing the right cell line for breast cancer research.

  Breast cancer research : BCR 20110101

• Discovering biological connections between experimental conditions based on common patterns of differential gene expression.

  BMC bioinformatics 20110101

• Platinum resistance in breast and ovarian cancer cell lines.

  Journal of experimental & clinical cancer research : CR 20110101

• Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

  Genome medicine 20110101

• The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.

  BMC cancer 20110101

• Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.

  Breast cancer research : BCR 20110101

• Male breast carcinoma: increased awareness needed.

  Breast cancer research : BCR 20110101

• Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

  Journal of the National Cancer Institute. Monographs 20110101

• Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer.

  Radiation oncology (London, England) 20110101

• Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.

  Breast cancer : basic and clinical research 20110101

• Protein biomarkers for the early detection of breast cancer.

  International journal of proteomics 20110101

• Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer.

  ISRN oncology 20110101

• Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy.

  PloS one 20110101

• Breast cancer in the lower jaw after reconstructive surgery with a pectoralis major myocutaneous flap (PMMC) -- a case report.

  European journal of medical research 20110101

• Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

  Breast cancer research : BCR 20110101

• Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications.

  TheScientificWorldJournal 20110101

• Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

  Health technology assessment (Winchester, England) 20110101

• Efficacy and safety of ultra-low-dose Vagifem (10 mcg).

  Patient preference and adherence 20110101

• The use of high dose letrozole in ovulation induction and controlled ovarian hyperstimulation.

  ISRN obstetrics and gynecology 20110101

• Regression of late onset choroidal metastasis from a breast carcinoma with letrozole.

  Case reports in ophthalmology 20110101

• Rosiglitazone and pioglitazone alter aromatase kinetic properties in human granulosa cells.

  PPAR research 20110101

• Review of breast conservation therapy: then and now.

  ISRN oncology 20110101

• The state of research into children with cancer across Europe: new policies for a new decade.

  Ecancermedicalscience 20110101

• Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.

  Chemotherapy research and practice 20110101

• Breast conservation surgery: state of the art.

  International journal of breast cancer 20110101

• The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer.

  International journal of breast cancer 20110101

• Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol.

  International journal of surgical oncology 20110101

• 17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in rats.

  International journal of breast cancer 20110101

• [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].

  Voprosy onkologii 20110101

• Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.

  Clinical sarcoma research 20110101

• Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

  Frontiers in endocrinology 20110101

• Cancer and renal insufficiency results of the BIRMA study.

  British journal of cancer 20101207

• Impact of the estrus cycle and reduction in estrogen levels with aromatase inhibition, on renal function and nitric oxide activity in female rats.

  Steroids 20101201

• Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.

  Cancer metastasis reviews 20101201

• Antimicrobial, antitumor and 5α-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones.

  European journal of medicinal chemistry 20101201

• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  The Lancet. Oncology 20101201

• 10 years of ATAC: one question answered, many others unresolved.

  The Lancet. Oncology 20101201

• [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101201

• In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.

  British journal of clinical pharmacology 20101201

• Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20101123

• Cognitive changes associated with endocrine therapy for breast cancer.

  Maturitas 20101101

• Synthesis of bioactive polyheterocyclic ring systems as 5α-reductase inhibitors.

  European journal of medicinal chemistry 20101101

• Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.

  European journal of cancer (Oxford, England : 1990) 20101101

• Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101

• What is the value of the 21 gene recurrence score in HER2-negative patients?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101

• Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.

  European journal of cancer (Oxford, England : 1990) 20101101

• Anastrozole.

  Expert opinion on drug safety 20101101

• Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.

  The oncologist 20101101

• [A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• 3-Ethyl-4-[3-(1H-imidazol-1-yl)prop-yl]-5-phenyl-4H-1,2,4-triazole dihydrate.

  Acta crystallographica. Section E, Structure reports online 20101101

• Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.

  Breast cancer (Tokyo, Japan) 20101001

• Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.

  Breast cancer (Tokyo, Japan) 20101001

• Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo.

  Fertility and sterility 20101001

• Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.

  Journal of clinical and experimental neuropsychology 20101001

• Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.

  Analytical and bioanalytical chemistry 20101001

• Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.

  Current medical research and opinion 20101001

• Prevention and treatment of side-effects of systemic treatment: bone loss.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101001

• Endocrine therapy for male breast cancer: rates of toxicity and adherence.

  Current oncology (Toronto, Ont.) 20101001

• Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT).

  Journal of pediatric endocrinology & metabolism : JPEM 20101001

• N-[(4-Amino-5-sulfanyl-idene-4,5-dihydro-1H-1,2,4-triazol-3-yl)meth-yl]-4-methyl-benzamide.

  Acta crystallographica. Section E, Structure reports online 20101001

• 3,3'-Dimethyl-4,4'-(hexane-1,6-di-yl)bis-[1H-1,2,4-triazol-5(4H)-one].

  Acta crystallographica. Section E, Structure reports online 20101001

• Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

  British journal of cancer 20100907

• ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.

  Breast cancer research and treatment 20100901

• Amelioration of sexual adverse effects in the early breast cancer patient.

  Journal of cancer survivorship : research and practice 20100901

• Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100901

• Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.

  Pediatrics 20100901

• Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.

  The oncologist 20100901

• Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100901

• Use of aromatase inhibitors in children and adolescents: what's new?

  Current opinion in pediatrics 20100801

• Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.

  Breast cancer research and treatment 20100801

• Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.

  Clinical breast cancer 20100801

• [An elderly advanced breast cancer with a good response to anastrozole].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100801

• [A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100801

• Early recurrence risk: aromatase inhibitors versus tamoxifen.

  Expert review of anticancer therapy 20100801

• Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.

  British journal of cancer 20100727

• Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.

  British journal of cancer 20100727

• Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100720

• Obesity and hormone therapy in breast cancer: an unfinished puzzle.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100720

• Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.

  Breast cancer (Tokyo, Japan) 20100701

• A simple, selective and rapid validated method for estimation of anastrazole in human plasma by liquid chromatography-tandem mass spectrometry and its application to bioequivalence study.

  Biomedical chromatography : BMC 20100701

• Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.

  Maturitas 20100701

• Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.

  Medical oncology (Northwood, London, England) 20100601

• Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.

  American journal of clinical oncology 20100601

• Aromatase inhibition in male breast cancer patients: biological and clinical implications.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100601

• Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion.

  European journal of endocrinology 20100601

• Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.

  Breast cancer research and treatment 20100601

• Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.

  Breast cancer research and treatment 20100601

• Rectal metastasis from lobular carcinoma of the breast: a case report.

  Collegium antropologicum 20100601

• [Inhibitory effect on estrogen production and its influence on invasive ability of human endometrial cells of endometriosis by medicated serum of SLW].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20100601

• Ethyl 4-(3-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-4-yl)benzoate.

  Acta crystallographica. Section E, Structure reports online 20100601

• Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation.

  International journal of pharmaceutics 20100531

• Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.

  Fertility and sterility 20100515

• Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).

  Bioorganic & medicinal chemistry letters 20100515

• Adjuvant aromatase inhibitor therapy: outcomes and safety.

  Cancer treatment reviews 20100501

• Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.

  Applied immunohistochemistry & molecular morphology : AIMM 20100501

• Comparison of the effects of raloxifene and anastrozole on experimental endometriosis.

  European journal of obstetrics, gynecology, and reproductive biology 20100501

• Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.

  Breast cancer research and treatment 20100501

• Adjuvant endocrine therapy for early breast cancer: the story so far.

  Cancer investigation 20100501

• [A case of recurrence of breast cancer 36 years after mastectomy treated with endocrine and chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100501

• Breast cancer in the personal genomics era.

  Current genomics 20100501

• Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

  Oncogene 20100422

• Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.

  Cancer research 20100415

• Epidemiology and pathophysiology of cancer-associated thrombosis.

  British journal of cancer 20100413

• Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410

• Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry.

  Analytical and bioanalytical chemistry 20100401

• Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.

  British journal of clinical pharmacology 20100401

• [Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].

  Zhonghua bing li xue za zhi = Chinese journal of pathology 20100401

• The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.

  British journal of cancer 20100330

• Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100315

• Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.

  Journal of medicinal chemistry 20100311

• [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].

  Zhonghua yi xue za zhi 20100302

• Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

  Gynecologic oncology 20100301

• Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301

• [Management of metastatic HER2-positive breast cancer: present and future].

  Bulletin du cancer 20100301

• Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.

  The oncologist 20100301

• Question 2. Which medications effectively reduce pubertal gynaecomastia?

  Archives of disease in childhood 20100301

• [Inhibitory effect of Jiawei Sanleng pill medicated serum on estrogen production and its influence on apoptosis of human endometrial cells of endometriosis].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20100301

• Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?

  The Journal of steroid biochemistry and molecular biology 20100227

• Impact of aromatase inhibitors on bone health in breast cancer patients.

  The Journal of steroid biochemistry and molecular biology 20100227

• Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.

  The Journal of steroid biochemistry and molecular biology 20100227

• Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

• Assessment of fracture risk in women with breast cancer using current vs emerging guidelines.

  British journal of cancer 20100216

• Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.

  Drug metabolism reviews 20100201

• Musculoskeletal manifestations in patients with malignant disease.

  Clinical rheumatology 20100201

• A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.

  Breast cancer research and treatment 20100201

• Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

  Cancer treatment reviews 20100201

• [A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].

  Journal des maladies vasculaires 20100201

• Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.

  Breast cancer research and treatment 20100201

• A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.

  Epilepsy & behavior : E&B 20100201

• Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature.

  Pharmacotherapy 20100201

• Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.

  Clinical breast cancer 20100201

• Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.

  The oncologist 20100201

• Management of hot flashes in women with breast cancer.

  Current oncology (Toronto, Ont.) 20100201

• Management of aromatase inhibitor-induced arthralgia.

  Current oncology (Toronto, Ont.) 20100201

• Endometriosis: in search of optimal treatment.

  Minerva ginecologica 20100201

• 1-Benzoyl-methyl-3-(2-thienylmeth-yl)-4-(2-thienylmethyl-eneamino)-1H-1,2,4-triazol-5(4H)-one.

  Acta crystallographica. Section E, Structure reports online 20100201

• Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.

  British journal of cancer 20100119

• A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.

  Breast cancer research and treatment 20100101

• Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

  Cancer research 20100101

• Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

  PloS one 20100101

• Accelerated hypofractionated radiotherapy as adjuvant regimen after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years.

  Journal of experimental & clinical cancer research : CR 20100101

• A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

  BMC cancer 20100101

• [Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].

  Voprosy onkologii 20100101

• Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

  Onkologie 20100101

• Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

  Breast cancer research : BCR 20100101

• Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?

  Current oncology reports 20100101

• Gynaecomastia: the anastrozole paradox.

  Journal of pediatric endocrinology & metabolism : JPEM 20100101

• Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

  PloS one 20100101

• Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

  Clinical Medicine Insights. Oncology 20100101

• Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.

  Breast cancer research : BCR 20100101

• Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.

  Breast cancer research : BCR 20100101

• Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report.

  Journal of medical case reports 20100101

• Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.

  Onkologie 20100101

• A rare case of breast cancer metastasis.

  Breast disease 20100101

• Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.

  Breast cancer research : BCR 20100101

• Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

  International journal of pediatric endocrinology 20100101

• The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.

  Cancer investigation 20100101

• Clinical practice decisions in endocrine therapy.

  Cancer investigation 20100101

• The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20100101

• Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.

  Breast cancer research : BCR 20100101

• Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.

  PloS one 20100101

• Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.

  Journal of oncology 20100101

• [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].

  Biomedica : revista del Instituto Nacional de Salud 20100101

• ExaCT: automatic extraction of clinical trial characteristics from journal publications.

  BMC medical informatics and decision making 20100101

• Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?

  Journal of cutaneous and aesthetic surgery 20100101

• Reduction of radiation pneumonitis by V20-constraints in breast cancer.

  Radiation oncology (London, England) 20100101

• Present and future evolution of advanced breast cancer therapy.

  Breast cancer research : BCR 20100101

• Women and bone health: maximizing the benefits of aromatase inhibitor therapy.

  Oncology 20100101

• Antiangiogenic therapy for breast cancer.

  Breast cancer research : BCR 20100101

• Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.

  Oncology 20100101

• The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service.

  BMC cancer 20100101

• Ligands specify estrogen receptor alpha nuclear localization and degradation.

  BMC cell biology 20100101

• Hot flashes in breast cancer survivors and an association with calcium supplement use.

  International journal of women's health 20100101

• Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study.

  International journal of women's health 20100101

• Prevention of bone metastases and management of bone health in early breast cancer.

  Breast cancer research : BCR 20100101

• Designing adjuvant treatment based on biological measurements in the neoadjuvant setting.

  Breast cancer research : BCR 20100101

• Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.

  Breast cancer research : BCR 20100101

• Evaluation of ketorolac tromethamine microspheres by chitosan/gelatin B complex coacervation.

  Scientia pharmaceutica 20100101

• Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.

  PloS one 20100101

• Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.

  Cancer management and research 20100101

• FACE: the barefaced facts of AI potency.

  Cancer management and research 20100101

• Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.

  Oncology 20100101

• Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.

  Drug, healthcare and patient safety 20100101

• Endometrial adenocarcinoma in a 27-year-old woman.

  Clinical medicine insights. Case reports 20100101

• Pharmacoeconomic considerations in the treatment of breast cancer.

  ClinicoEconomics and outcomes research : CEOR 20100101

• The role of funding and policies on innovation in cancer drug development.

  Ecancermedicalscience 20100101

• Safe practice and nursing care of patients receiving oral anti-cancer medicines: a position statement from UKONS.

  Ecancermedicalscience 20100101

• Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.

  BMJ case reports 20100101

• Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.

  Indian journal of surgical oncology 20100101

• Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.

  Ontario health technology assessment series 20100101

• Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.

  Journal of medicinal chemistry 20091210

• Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.

  The Journal of clinical endocrinology and metabolism 20091201

• CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.

  British journal of cancer 20091201

• CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.

  British journal of cancer 20091201

• Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.

  Minerva ginecologica 20091201

• Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.

  Best practice & research. Clinical rheumatology 20091201

• Testosterone: more is not always better.

  The Journal of clinical endocrinology and metabolism 20091201

• [A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor.

  Journal of pediatric endocrinology & metabolism : JPEM 20091201

• Aromatase inhibitors to augment height: continued caution and study required.

  Journal of clinical research in pediatric endocrinology 20091201

• How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

• Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro.

  The Journal of steroid biochemistry and molecular biology 20091101

• Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.

  Anticancer research 20091101

• [A case of inflammatory breast cancer responding to anastrozole].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

  British journal of cancer 20091020

• LC and LC-MS/MS study of forced decomposition behavior of anastrozole and establishment of validated stability-indicating analytical method for impurities estimation in low dose anastrozole tablets.

  Journal of pharmaceutical and biomedical analysis 20091015

• Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

  The Cochrane database of systematic reviews 20091007

• Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs.

  Clinical & experimental metastasis 20091001

• Effects of morphine on testosterone levels in rat C6 glioma cells: modulation by anastrozole.

  Journal of cellular physiology 20091001

• Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.

  Critical reviews in oncology/hematology 20091001

• Medical treatment for rectovaginal endometriosis: what is the evidence?

  Human reproduction (Oxford, England) 20091001

• Aromatase inhibitors for female infertility: a systematic review of the literature.

  Reproductive biomedicine online 20091001

• Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Tamoxifen: the drug that came in from the cold.

  British journal of cancer 20090915

• Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial.

  Fertility and sterility 20090901

• Vitreo-retinal traction and anastrozole use.

  Breast cancer research and treatment 20090901

• Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.

  Breast cancer research and treatment 20090901

• Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Breast cancer chemoprevention - a vision not yet realized.

  European journal of cancer care 20090901

• Strategies for maximizing growth in puberty in children with short stature.

  Endocrinology and metabolism clinics of North America 20090901

• [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.

  Internal medicine journal 20090901

• Treatment of autonomous ovarian follicular cyst with long-term anastrozole therapy.

  Indian journal of pediatrics 20090901

• Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.

  Drugs 20090820

• Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.

  British journal of cancer 20090818

• A suite of activity-based probes for human cytochrome P450 enzymes.

  Journal of the American Chemical Society 20090805

• Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.

  Breast cancer research and treatment 20090801

• Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.

  Psycho-oncology 20090801

• Improved survival in patients with breast rhabdoid tumors with multi-agent adjuvant chemotherapy combined with irradiation.

  Cancer chemotherapy and pharmacology 20090801

• Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.

  The Journal of clinical endocrinology and metabolism 20090801

• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090801

• Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.

  Cancer biology & therapy 20090801

• Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.

  Breast (Edinburgh, Scotland) 20090801

• A remarkable case of cutaneous metastatic breast carcinoma.

  Dermatology online journal 20090715

• Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.

  Dermatology online journal 20090715

• The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090701

• Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.

  Onkologie 20090701

• Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.

  Onkologie 20090701

• Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20090701

• Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.

  The Annals of pharmacotherapy 20090701

• An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

  Current oncology (Toronto, Ont.) 20090701

• Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

  Current oncology (Toronto, Ont.) 20090701

• Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen.

  Reproduction in domestic animals = Zuchthygiene 20090701

• Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.

  Journal of cancer research and clinical oncology 20090601

• History of aromatase: saga of an important biological mediator and therapeutic target.

  Endocrine reviews 20090601

• 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.

  Breast (Edinburgh, Scotland) 20090601

• Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.

  Expert opinion on pharmacotherapy 20090601

• Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.

  Cancer research 20090601

• Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.

  Anticancer research 20090601

• Enhancing the efficacy of hormonal agents with selected targeted agents.

  Clinical breast cancer 20090601

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison.

  Fertility and sterility 20090501

• Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review.

  Breast cancer research and treatment 20090501

• A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.

  Cancer 20090501

• Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study.

  European journal of obstetrics, gynecology, and reproductive biology 20090501

• Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.

  Current medical research and opinion 20090501

• [Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-year tamoxifen treatment - a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [Inhibitory effect of Sanlengwan on expression of adhesion molecules ICAM-1, CD44 in rats of endometriosis].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20090501

• 2-Benzoylmethyl-4-[(2-benzylidene-ethylidene)amino]-5-(2-thienylmethyl)-2H-1,2,4-triazol-3(4H)-one.

  Acta crystallographica. Section E, Structure reports online 20090501

• 4-[(E)-4-Methoxy-benzyl-ideneamino]-3-{1-[4-(2-methyl-prop-yl)phen-yl]eth-yl}-1H-1,2,4-triazole-5(4H)-thione.

  Acta crystallographica. Section E, Structure reports online 20090501

• A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.

  Breast cancer research and treatment 20090401

• Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.

  European journal of obstetrics, gynecology, and reproductive biology 20090401

• Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.

  Breast (Edinburgh, Scotland) 20090401

• [A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090401

• By the way, doctor. I'm 78. I had breast cancer nine years ago and have been taking Arimidex for six years. I have pain and some bleeding after intercourse, despite using Astroglide. My gynecologist prescribed vaginal estrogen cream. Is that safe for me?

  Harvard women's health watch 20090401

• Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

  Clinical medicine. Therapeutics 20090331

• Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

  British journal of cancer 20090310

• Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.

  Journal of the National Cancer Institute 20090304

• Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

  European journal of cancer (Oxford, England : 1990) 20090301

• Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

  The Journal of clinical endocrinology and metabolism 20090301

• Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• Future targets in endometriosis treatment: targeting the endometriotic implant.

  Mini reviews in medicinal chemistry 20090301

• [Adjuvant breast cancer treatment with hormono-radiotherapy].

  Bulletin du cancer 20090301

• 3-[1-(4-Isobutyl-phen-yl)eth-yl]-1H-1,2,4-triazole-5(4H)-thione.

  Acta crystallographica. Section E, Structure reports online 20090301

• The total hospital and community UK costs of managing patients with relapsed breast cancer.

  British journal of cancer 20090224

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090212

• Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.

  British journal of cancer 20090210

• A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole.

  Archives of gynecology and obstetrics 20090201

• Treating elderly patients with hormone sensitive breast cancer: what do the data show?

  Cancer treatment reviews 20090201

• Aromatase inhibitors and bone health.

  Current opinion in obstetrics & gynecology 20090201

• Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

  Journal of the National Comprehensive Cancer Network : JNCCN 20090201

• [A case of metastatic breast cancer with liver metastasis effectively treated with capecitabine and vinorelbine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090201

• Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.

  Annals of the New York Academy of Sciences 20090201

• Aromatase inhibitors and breast cancer.

  Annals of the New York Academy of Sciences 20090201

• A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.

  Clinical breast cancer 20090201

• Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.

  Fertility and sterility 20090101

• Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.

  Archives of gynecology and obstetrics 20090101

• Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20090101

• A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.

  American journal of obstetrics and gynecology 20090101

• Effects of 17beta-estradiol on rat urinary bladder: gender differences in anoxia-glucopenia and reperfusion damage.

  Neurourology and urodynamics 20090101

• Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility.

  Acta obstetricia et gynecologica Scandinavica 20090101

• The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

  Urologic oncology 20090101

• Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.

  Cancer nursing 20090101

• Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer.

  BMC cancer 20090101

• Update on the role of aromatase inhibitors in growth disorders.

  Hormone research 20090101

• Prevalence, sources, and predictors of soy consumption in breast cancer.

  Nutrition journal 20090101

• [Clinical course of multiple sclerosis in patients treated with cytostatic drugs for cancer].

  Revista de neurologia 20090101

• Breast cancer in young women and its impact on reproductive function.

  Human reproduction update 20090101

• Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

  Breast cancer research : BCR 20090101

• Gynecomastia: what the surgeon needs to know.

  Eplasty 20090101

• Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis.

  Neoplasma 20090101

• Diagnosis and treatment of early breast cancer, including locally advanced disease--summary of NICE guidance.

  BMJ (Clinical research ed.) 20090101

• Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.

  Breast cancer (Tokyo, Japan) 20090101

• Collaborative work on evaluation of ovarian toxicity. 8) Two- or four-week repeated-dose studies and fertility study of Anastrozole in female rats.

  The Journal of toxicological sciences 20090101

• Successful desensitisation to Anastrozole.

  Allergologia et immunopathologia 20090101

• Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.

  American journal of therapeutics 20090101

• Enhancing the adjuvant treatment of hormone receptor positive breast cancer.

  The breast journal 20090101

• Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.

  Experimental gerontology 20090101

• Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.

  BMC cancer 20090101

• Internal auditory canal metastasis mimicking a vestibular schwannoma at presentation - a case report and review of the literature.

  International seminars in surgical oncology : ISSO 20090101

• Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach.

  Journal of experimental & clinical cancer research : CR 20090101

• The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.

  Reproductive biology and endocrinology : RB&E 20090101

• A review of the use of exemestane in early breast cancer.

  Therapeutics and clinical risk management 20090101

• Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells.

  PloS one 20090101

• A case of brain metastases from breast cancer that responded to anastrozole monotherapy.

  The breast journal 20090101

• Ruptured gallbladder as the first presentation of breast cancer.

  World journal of surgical oncology 20090101

• Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

  Trials 20090101

• Henoch-Schönlein purpura and aromatase inhibitors.

  European journal of dermatology : EJD 20090101

• In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

  BMC cancer 20090101

• Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.

  Breast cancer research : BCR 20090101

• Current trends in the treatment of polycystic ovary syndrome with desire for children.

  Therapeutics and clinical risk management 20090101

• The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.

  BMC medical genomics 20090101

• Alternative use of multiple exons 1 of aromatase gene in cancerous and normal breast tissues from women over the age of 80 years.

  Breast cancer research : BCR 20090101

• [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].

  Voprosy onkologii 20090101

• Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

  BMC cancer 20090101

• The benefits and risks of testosterone replacement therapy: a review.

  Therapeutics and clinical risk management 20090101

• HER2 breast cancer therapies: a review.

  Biologics : targets & therapy 20090101

• Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

  Breast cancer research : BCR 20090101

• Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil.

  Revista da Associacao Medica Brasileira (1992) 20090101

• Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women.

  Therapeutics and clinical risk management 20090101

• Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.

  Therapeutics and clinical risk management 20090101

• A system for computerised retinal haemorrhage analysis.

  BMC research notes 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Can survival prediction be improved by merging gene expression data sets?

  PloS one 20090101

• Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

  Journal of hematology & oncology 20090101

• Update on the use of aromatase inhibitors in early-stage breast cancer.

  Breast cancer research : BCR 20090101

• Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.

  World journal of surgical oncology 20090101

• [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer].

  Revista da Associacao Medica Brasileira (1992) 20090101

• Antiproliferative effect of exemestane in lung cancer cells.

  Molecular cancer 20090101

• Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men.

  Urologia internationalis 20090101

• Who would have thought a single Ki67 measurement would predict long-term outcome?

  Breast cancer research : BCR 20090101

• Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? The scenario.

  Breast cancer research : BCR 20090101

• Foundation clinical trials.

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.

  Breast cancer research : BCR 20090101

• Tailored targeted therapy for all: a realistic and worthwhile objective against.

  Breast cancer research : BCR 20090101

• Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.

  International journal of general medicine 20090101

• The evolving role of zoledronic acid in early breast cancer.

  OncoTargets and therapy 20090101

• Aromatase inhibitor strategies in metastatic breast cancer.

  International journal of women's health 20090101

• Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.

  Breast cancer : basic and clinical research 20090101

• Osteoporosis after breast cancer chemotherapy: a case report.

  The Ochsner journal 20090101

• The evolution of treatment for early breast cancer: what's next?

  Ecancermedicalscience 20090101

• Role of traditional and new biomarkers in breast carcinogenesis.

  Ecancermedicalscience 20090101

• Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.

  British journal of cancer 20081209

• Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.

  Breast (Edinburgh, Scotland) 20081201

• Never too late: reducing late breast cancer relapse risk.

  Current medical research and opinion 20081201

• Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

  The Lancet. Oncology 20081201

• Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.

  Expert review of anticancer therapy 20081201

• Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.

  Breast cancer research and treatment 20081201

• Are all aromatase inhibitors alike?

  Breast cancer research and treatment 20081201

• Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.

  Clinical interventions in aging 20081201

• Exemestane in early breast cancer: a review.

  Therapeutics and clinical risk management 20081201

• The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.

  Journal of gynecologic oncology 20081201

• 3-[1-(4-Isobutyl-phen-yl)eth-yl]-4-[(E)-4-methyl-benzyl-ideneamino]-1H-1,2,4-triazole-5(4H)-thione.

  Acta crystallographica. Section E, Structure reports online 20081201

• Development and validation of an improved high-throughput method for the determination of anastrozole in human plasma by LC-MS/MS and atmospheric pressure chemical ionization.

  Journal of pharmaceutical and biomedical analysis 20081104

• Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.

  British journal of cancer 20081104

• Aromatase inhibitors in the management of early breast cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20081101

• Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.

  Fertility and sterility 20081101

• Cutaneous vasculitis in breast cancer treated with chemotherapy.

  Clinical immunology (Orlando, Fla.) 20081001

• Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).

  The Lancet. Oncology 20081001

• Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

  Journal of the National Cancer Institute 20081001

• Estrogen, testosterone, and sequential movement in men.

  Behavioral neuroscience 20081001

• Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.

  International journal of clinical oncology 20081001

• Anastrozole: brain draining or sparing?

  The Lancet. Oncology 20081001

• Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty.

  Journal of pediatric endocrinology & metabolism : JPEM 20081001

• Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

  Journal of the National Cancer Institute 20080917

• Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

  Journal of the National Cancer Institute 20080917

• Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.

  American journal of obstetrics and gynecology 20080901

• Skeletal effects of drugs to treat cancer.

  Current drug safety 20080901

• Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

  The Lancet. Oncology 20080901

• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

  The Lancet. Oncology 20080901

• Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20080901

• IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

  Expert review of anticancer therapy 20080901

• Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).

  Health expectations : an international journal of public participation in health care and health policy 20080901

• Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.

  Drugs of today (Barcelona, Spain : 1998) 20080901

• tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.

  British journal of cancer 20080819

• Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.

  Bioorganic & medicinal chemistry letters 20080815

• Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer.

  British journal of cancer 20080805

• Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.

  Surgical oncology 20080801

• Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial.

  Human reproduction (Oxford, England) 20080801

• Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?

  Breast (Edinburgh, Scotland) 20080801

• Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor.

  Obstetrics and gynecology 20080801

• Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.

  Clinical breast cancer 20080801

• Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.

  Clinical breast cancer 20080801

• Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.

  The journal of obstetrics and gynaecology research 20080801

• The endocrine prevention of breast cancer.

  Best practice & research. Clinical endocrinology & metabolism 20080801

• 4-[(E)-2-Furylmethyl-eneamino]-3-phenyl-1H-1,2,4-triazole-5(4H)-thione.

  Acta crystallographica. Section E, Structure reports online 20080801

• MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.

  Biochemical pharmacology 20080715

• The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands.

  Breast cancer research and treatment 20080701

• Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080701

• The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20080701

• The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.

  The Journal of clinical endocrinology and metabolism 20080701

• Treatment of male infertility secondary to morbid obesity.

  Nature clinical practice. Endocrinology & metabolism 20080701

• Experience with exemestane in the treatment of early and advanced breast cancer.

  Expert opinion on drug metabolism & toxicology 20080701

• A novel method for assessing sex-specific and genotype-specific response to injury in astrocyte culture.

  Journal of neuroscience methods 20080630

• Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.

  Cancer research 20080615

• Risks and benefits of bisphosphonates.

  British journal of cancer 20080603

• The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer.

  Breast cancer research and treatment 20080601

• Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.

  Journal of cancer research and clinical oncology 20080601

• Effectively nursing patients receiving aromatase inhibitor therapy.

  Breast (Edinburgh, Scotland) 20080601

• Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

  Expert opinion on pharmacotherapy 20080601

• Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?

  Cancer investigation 20080601

• [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].

  Magyar onkologia 20080601

• [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].

  Magyar onkologia 20080601

• Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles.

  Drug delivery 20080601

• [Inhibitory effects of Sanlengwan on aromatase and cyclooxygenase-2 in rats of endometriosis].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20080601

• Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.

  British journal of cancer 20080506

• Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.

  The European journal of health economics : HEPAC : health economics in prevention and care 20080501

• Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial.

  Fertility and sterility 20080501

• CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.

  Drug metabolism and disposition: the biological fate of chemicals 20080501

• Process analytical technology: non-destructive assessment of anastrozole entrapment within PLGA microparticles by near infrared spectroscopy and chemical imaging.

  Journal of microencapsulation 20080501

• Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.

  Cancer research 20080501

• The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080501

• Retinal hemorrhages in anastrozole users.

  Optometry and vision science : official publication of the American Academy of Optometry 20080501

• Targeting breast cancer with hormonal treatment options.

  The Nurse practitioner 20080501

• Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

  Cancer treatment reviews 20080401

• Aromatase inhibitors in early breast-cancer treatment: The story so far.

  Breast (Edinburgh, Scotland) 20080401

• Inappropriate ATAC on tamoxifen.

  The Lancet. Oncology 20080401

• Inappropriate ATAC on tamoxifen.

  The Lancet. Oncology 20080401

• Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401

• [A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080401

• Neoadjuvant endocrine therapy for breast cancer: past, present and future.

  Anti-cancer drugs 20080401

• Anastrozole-induced subacute cutaneous lupus erythematosus.

  The British journal of dermatology 20080301

• Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.

  The Journal of clinical endocrinology and metabolism 20080301

• Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.

  Annals of surgical oncology 20080301

• Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301

• Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301

• Menopausal symptoms and adjuvant therapy-associated adverse events.

  Endocrine-related cancer 20080301

• Anticancer therapy in patients with porphyrias: evidence today.

  Expert opinion on drug safety 20080301

• Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.

  Anti-cancer drugs 20080301

• Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?

  Anti-cancer drugs 20080301

• [The effect of hormone therapy on cognitive function in patients with breast cancer].

  Nederlands tijdschrift voor geneeskunde 20080301

• [Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].

  Praxis 20080206

• Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.

  Nature clinical practice. Oncology 20080201

• New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation.

  Bioorganic & medicinal chemistry 20080201

• Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.

  Cancer 20080201

• Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.

  Cancer 20080201

• Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201

• [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• [A 23-year delayed locoregional recurrence of breast carcinoma following mastectomy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.

  Breast (Edinburgh, Scotland) 20080201

• Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.

  Clinical breast cancer 20080201

• Long-term safety of aromatase inhibitors in the treatment of breast cancer.

  Therapeutics and clinical risk management 20080201

• The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080101

• Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials.

  Journal of cancer research and clinical oncology 20080101

• Aromatase inhibitors: past, present and future in breast cancer therapy.

  Medical oncology (Northwood, London, England) 20080101

• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

  The Lancet. Oncology 20080101

• ERBB2 status and outcome of endocrine treatment.

  The Lancet. Oncology 20080101

• Long-term outcomes of aromatase inhibition for breast cancer.

  The Lancet. Oncology 20080101

• Chemoprevention of breast cancer.

  Breast cancer (Tokyo, Japan) 20080101

• Aromatase inhibitors: from bench to bedside and back.

  Breast cancer (Tokyo, Japan) 20080101

• Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.

  Current oncology (Toronto, Ont.) 20080101

• Cancer treatment-related bone loss: a review and synthesis of the literature.

  Current oncology (Toronto, Ont.) 20080101

• Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.

  Breast cancer (Tokyo, Japan) 20080101

• The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.

  Breast (Edinburgh, Scotland) 20080101

• Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.

  BMC cancer 20080101

• [Adjuvant treatment of operable breast cancer].

  Anales de medicina interna (Madrid, Spain : 1984) 20080101

• Caecal metastasis from breast cancer presenting as intestinal obstruction.

  World journal of surgical oncology 20080101

• Cancer and fertility preservation: fertility preservation in breast cancer patients.

  Breast cancer research : BCR 20080101

• Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the internet.

  The breast journal 20080101

• Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

  Drugs 20080101

• What do perceived cognitive problems reflect?

  The journal of supportive oncology 20080101

• Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.

  Breast cancer research : BCR 20080101

• New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.

  BMC cell biology 20080101

• Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue.

  BMC cancer 20080101

• Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.

  Trials 20080101

• HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

  PloS one 20080101

• Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.

  PloS one 20080101

• The growth-promoting action of individual women's sera on mammary carcinoma cells.

  Anticancer research 20080101

• Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.

  Journal of experimental & clinical cancer research : CR 20080101

• Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.

  Breast cancer (Tokyo, Japan) 20080101

• Use of letrozole in assisted reproduction: a systematic review and meta-analysis.

  Human reproduction update 20080101

• Infertility and the provision of infertility medical services in developing countries.

  Human reproduction update 20080101

• Novel therapies in breast cancer: what is new from ASCO 2008.

  Journal of hematology & oncology 20080101

• Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

  Breast cancer research : BCR 20080101

• Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?

  The breast journal 20080101

• Chemopreventive effects of anastrozole in a premenopausal breast cancer model.

  Anticancer research 20080101

• The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma.

  World journal of surgical oncology 20080101

• Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

  Breast cancer research : BCR 20080101

• A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.

  World journal of surgical oncology 20080101

• By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.

  Breast cancer research : BCR 20080101

• Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.

  Breast cancer research : BCR 20080101

• Markers of endocrine sensitivity.

  Breast cancer research : BCR 20080101

• Identification and mechanisms of endocrine resistance.

  Breast cancer research : BCR 20080101

• Integration of endocrine therapy with targeted agents.

  Breast cancer research : BCR 20080101

• Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

  Breast cancer research : BCR 20080101

• Neoadjuvant/presurgical treatments.

  Breast cancer research : BCR 20080101

• Evaluation of biological agents targeted at early-stage disease.

  Breast cancer research : BCR 20080101

• Optimizing the implementation of future treatment using surrogate end-points.

  Breast cancer research : BCR 20080101

• Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against.

  Breast cancer research : BCR 20080101

• Roles of prohibitin in growth control and tumor suppression in human cancers.

  Translational oncogenomics 20080101

• Cancer care in Singapore.

  Biomedical imaging and intervention journal 20080101

• Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.

  Biomedical imaging and intervention journal 20080101

• Response of cutaneous metastases from breast cancer to capecitabine.

  Clinical medicine. Oncology 20080101

• Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers.

  Ecancermedicalscience 20080101

• Extended adjuvant therapy for breast cancer--how much is enough?

  Journal of the National Cancer Institute 20071219

• Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

  Journal of the National Cancer Institute 20071219

• Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.

  Breast cancer research and treatment 20071201

• Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.

  Breast cancer research and treatment 20071201

• Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.

  Journal of cancer research and clinical oncology 20071201

• Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.

  Cancer treatment reviews 20071201

• The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.

  International journal of clinical practice 20071201

• Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.

  Joint, bone, spine : revue du rhumatisme 20071201

• Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20071201

• Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.

  Breast cancer research and treatment 20071201

• Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.

  International journal of radiation oncology, biology, physics 20071201

• Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.

  Breast (Edinburgh, Scotland) 20071201

• Treatment of bicalutamide-induced breast events.

  Expert review of anticancer therapy 20071201

• [Solitary oesophageal metastasis of breast cancer after 17 years latency].

  Magyar sebeszet 20071201

• Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.

  Seminars in oncology 20071201

• Management of arthralgias associated with aromatase inhibitor therapy.

  Current oncology (Toronto, Ont.) 20071201

• Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

  Current oncology (Toronto, Ont.) 20071201

• Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada.

  Current oncology (Toronto, Ont.) 20071201

• Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.

  Clinical breast cancer 20071201

• Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.

  Critical reviews in oncology/hematology 20071101

• The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.

  Current opinion in oncology 20071101

• Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.

  The Journal of rheumatology 20071101

• Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071101

• Progression of endocrine therapies for breast cancer: where are we headed?

  Expert review of anticancer therapy 20071101

• Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

  European journal of cancer (Oxford, England : 1990) 20071101

• Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.

  Organic & biomolecular chemistry 20071021

• Letrozole in advanced breast cancer: the PO25 trial.

  Breast cancer research and treatment 20071001

• Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.

  Breast (Edinburgh, Scotland) 20071001

• Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.

  Breast (Edinburgh, Scotland) 20071001

• Severe disabling tendinopathy caused by anastrazole.

  Rheumatology (Oxford, England) 20071001

• Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.

  The journal of obstetrics and gynaecology research 20071001

• Aromatase inhibitor and bone.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20071001

• The discovery and mechanism of action of letrozole.

  Breast cancer research and treatment 20071001

• Letrozole in the neoadjuvant setting: the P024 trial.

  Breast cancer research and treatment 20071001

• Letrozole in the extended adjuvant setting: MA.17.

  Breast cancer research and treatment 20071001

• Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.

  Breast cancer research and treatment 20071001

• A decade of letrozole: FACE.

  Breast cancer research and treatment 20071001

• Safety of aromatase inhibitors in the adjuvant setting.

  Breast cancer research and treatment 20071001

• The patient experience.

  Breast cancer research and treatment 20071001

• Femara and the future: tailoring treatment and combination therapies with Femara.

  Breast cancer research and treatment 20071001

• Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.

  Expert opinion on pharmacotherapy 20071001

• [A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20071001

• Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.

  The Journal of reproductive medicine 20071001

• Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.

  Organic & biomolecular chemistry 20070921

• Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

  British journal of cancer 20070911

• [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].

  Ugeskrift for laeger 20070910

• Unusual macular degeneration following breast cancer.

  Acta ophthalmologica Scandinavica 20070901

• Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

  Bone 20070901

• Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).

  Anti-cancer drugs 20070901

• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• The effect of anastrazole on symptomatic uterine leiomyomata.

  Obstetrics and gynecology 20070901

• Reducing the risk of late recurrence in hormone-responsive breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Reducing the risk of early recurrence in hormone-responsive breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Effect of estrogens on skin aging and the potential role of SERMs.

  Clinical interventions in aging 20070901

• Nonsurgical treatment of male infertility: specific and empiric therapy.

  Biologics : targets & therapy 20070901

• Nanomolar concentrations of anabolic-androgenic steroids amplify excitotoxic neuronal death in mixed mouse cortical cultures.

  Brain research 20070824

• Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.

  British journal of cancer 20070820

• Bone density in breast cancer: when to intervene?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.

  Obstetrics and gynecology 20070801

• Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.

  Clinical breast cancer 20070801

• Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

  Clinical therapeutics 20070801

• Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.

  Minerva ginecologica 20070801

• The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.

  Expert review of anticancer therapy 20070801

• Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.

  British journal of cancer 20070716

• Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

  Cancer 20070715

• Optimal use of aromatase inhibitors: to lead or to follow?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• Hormonal therapies for early breast cancer: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20070701

• Fulvestrant (Faslodex) -- how to make a good drug better.

  The oncologist 20070701

• Adjuvant endocrine therapy for early breast cancer.

  Cancer letters 20070618

• Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience.

  British journal of cancer 20070618

• Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

  Breast (Edinburgh, Scotland) 20070601

• Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist.

  Fertility and sterility 20070601

• Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer.

  Breast (Edinburgh, Scotland) 20070601

• Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.

  The Journal of clinical endocrinology and metabolism 20070601

• Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.

  International journal of radiation oncology, biology, physics 20070601

• New advances in ovulation induction.

  Current opinion in obstetrics & gynecology 20070601

• The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.

  Current oncology (Toronto, Ont.) 20070601

• Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.

  Clinical journal of oncology nursing 20070601

• Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070520

• Anastrozole quantification in human plasma by high-performance liquid chromatography coupled to photospray tandem mass spectrometry applied to pharmacokinetic studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole.

  Clinical and experimental dermatology 20070501

• The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

  Expert review of anticancer therapy 20070501

• Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.

  Current medical research and opinion 20070501

• Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.

  British journal of cancer 20070423

• Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

  Cancer letters 20070418

• [Clinical study of aromatase inhibitors in advanced breast cancer].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20070418

• Impact of aromatase inhibitors on adhesion formation in a rat model.

  Fertility and sterility 20070401

• [Advancement in endocrine therapy for breast cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20070401

• Parotid gland metastasis of a breast cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20070401

• Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer.

  Expert review of pharmacoeconomics & outcomes research 20070401

• Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.

  Cancer 20070315

• Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.

  Breast cancer research and treatment 20070301

• Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• [A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• Aromatase inhibitors: a safety comparison.

  Expert opinion on drug safety 20070301

• Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.

  Cancer investigation 20070301

• Trastuzumab in the management of early and advanced stage breast cancer.

  Biologics : targets & therapy 20070301

• Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.

  Journal of neurochemistry 20070201

• Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?

  American heart journal 20070201

• Pharmacogenetics and oncology treatment for breast cancer.

  Expert opinion on pharmacotherapy 20070201

• Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors.

  Onkologie 20070201

• The prevention and management of distant metastases in women with breast cancer.

  Cancer investigation 20070201

• The FACE trial: letrozole or anastrozole as initial adjuvant therapy?

  Cancer investigation 20070201

• A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20070201

• Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

  The Cochrane database of systematic reviews 20070124

• Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

  Journal of the National Cancer Institute 20070117

• Severe acute hepatitis in a patient treated with anastrozole.

  Lancet (London, England) 20070106

• Role of P450 aromatase in sex-specific astrocytic cell death.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20070101

• Henoch-Schönlein purpura (HSP) during treatment with anastrozole.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

  Steroids 20070101

• Anastrozole had a better risk-benefit profile than tamoxifen as adjuvant treatment for breast cancer in postmenopausal women.

  ACP journal club 20070101

• Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.

  The breast journal 20070101

• [Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

  Breast cancer (Tokyo, Japan) 20070101

• Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.

  BMC cancer 20070101

• Estrogen deprivation for breast cancer prevention.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101

• Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.

  Oncology (Williston Park, N.Y.) 20070101

• Neoadjuvant use of endocrine therapy in breast cancer.

  The breast journal 20070101

• Molecular response to aromatase inhibitor treatment in primary breast cancer.

  Breast cancer research : BCR 20070101

• Quality of life issues in relation to the aromatase inhibitor.

  The Journal of steroid biochemistry and molecular biology 20070101

• External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

  BMC cancer 20070101

• Aromatase inhibitors in ovarian stimulation.

  The Journal of steroid biochemistry and molecular biology 20070101

• DCIS and aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20070101

• New experimental models for aromatase inhibitor resistance.

  The Journal of steroid biochemistry and molecular biology 20070101

• Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature.

  World journal of surgical oncology 20070101

• EGFR associated expression profiles vary with breast tumor subtype.

  BMC genomics 20070101

• Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.

  Menopause (New York, N.Y.) 20070101

• Can a single model explain both breast cancer and prostate cancer?

  Theoretical biology & medical modelling 20070101

• Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.

  Breast cancer research : BCR 20070101

• Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.

  Menopause (New York, N.Y.) 20070101

• A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States.

  Journal of the International Society of Sports Nutrition 20070101

• Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males.

  Journal of the International Society of Sports Nutrition 20070101

• [Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].

  Voprosy onkologii 20070101

• Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.

  Breast cancer research : BCR 20070101

• Live or let die: oestrogen regulation of survival signalling in endocrine response.

  Breast cancer research : BCR 20070101

• Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

  Breast cancer research : BCR 20070101

• Overview of resistance to systemic therapy in patients with breast cancer.

  Advances in experimental medicine and biology 20070101

• [Neoadjuvant endocrine therapy for locally advanced breast cancer].

  La Clinica terapeutica 20070101

• Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer.

  Drugs 20070101

• The effects of anastrozole on neonatal rat skin.

  European journal of gynaecological oncology 20070101

• Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.

  Oncology 20070101

• Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.

  Open medicine : a peer-reviewed, independent, open-access journal 20070101

• [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

  Nederlands tijdschrift voor geneeskunde 20061230

• Anastrozole improved testosterone-induced impairment acquisition of spatial learning and memory in the hippocampal CA1 region in adult male rats.

  Behavioural brain research 20061215

• Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210

• Photodynamic therapy for solitary retinal metastasis from breast carcinoma.

  Eye (London, England) 20061201

• Quality of life of postmenopausal women in the ATAC ('Arimidex', tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.

  Breast cancer research and treatment 20061201

• A prospective randomized trial comparing anastrozole and clomiphene citrate in an ovulation induction protocol using gonadotropins.

  Fertility and sterility 20061201

• Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

  The Journal of steroid biochemistry and molecular biology 20061201

• What do we know about the mechanisms of aromatase inhibitor resistance?

  The Journal of steroid biochemistry and molecular biology 20061201

• Clinically occult cutaneous metastases.

  Journal of the American Academy of Dermatology 20061201

• Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.

  The Lancet. Oncology 20061201

• Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

  Seminars in oncology 20061201

• Is estradiol mandatory for an adequate follicular and embryo development? A mouse model using aromatase inhibitor (anastrozole).

  Journal of assisted reproduction and genetics 20061201

• Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

  Expert opinion on pharmacotherapy 20061201

• Non-steroidal anti-estrogens in the treatment of breast cancer.

  Current opinion in investigational drugs (London, England : 2000) 20061201

• Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.

  Current medical research and opinion 20061201

• Aromatase inhibitors and bone health in women with breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.

  Breast cancer research and treatment 20061101

• Correlates of use of different types of complementary and alternative medicine by breast cancer survivors in the nurses' health study.

  Breast cancer research and treatment 20061101

• Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.

  Gynecologic oncology 20061101

• Metastatic breast cancer: an updating.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20061101

• Optimal sequence of hormonotherapy in advanced breast cancer.

  Current opinion in oncology 20061101

• Safety of adjuvant aromatase inhibitor therapy.

  Cancer treatment reviews 20061101

• Anastrozole-induced hepatotoxicity.

  European journal of gastroenterology & hepatology 20061101

• Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.

  Cancer research 20061101

• Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

  Journal of the National Comprehensive Cancer Network : JNCCN 20061101

• Effects of adjuvant aromatase inhibitor therapy on lipid profiles.

  Expert review of anticancer therapy 20061101

• [Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• Aromatase inhibitors: structural features and biochemical characterization.

  Annals of the New York Academy of Sciences 20061101

• Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

  Breast (Edinburgh, Scotland) 20061001

• Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.

  Breast cancer research and treatment 20061001

• Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.

  Breast cancer research and treatment 20061001

• Update on the use of aromatase inhibitors in breast cancer.

  Expert opinion on pharmacotherapy 20061001

• Aromatase inhibitors and bipolar mood disorder: a case report.

  Bipolar disorders 20061001

• Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.

  Expert review of anticancer therapy 20061001

• Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

  Journal of the National Cancer Institute 20060920

• Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

  British journal of cancer 20060918

• Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060901

• Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole.

  The Journal of pediatrics 20060901

• Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.

  Anti-cancer drugs 20060901

• Pure oestrogen antagonists for the treatment of advanced breast cancer.

  Endocrine-related cancer 20060901

• Formulation of anastrozole microparticles as biodegradable anticancer drug carriers.

  AAPS PharmSciTech 20060901

• The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.

  Reviews on recent clinical trials 20060901

• The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.

  Reviews on recent clinical trials 20060901

• [Unclear about anastrozole and cancer treatment].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20060824

• Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.

  Breast (Edinburgh, Scotland) 20060801

• A double-blind randomised trial to evaluate the effect of anastrozole for the treatment of non-toxic multinodular goitre.

  International journal of clinical practice 20060801

• Information provision for patients by breast cancer teams about the side-effects of hormone treatments.

  European journal of cancer (Oxford, England : 1990) 20060801

• Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.

  Cancer 20060801

• Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060801

• Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

  Current medical research and opinion 20060801

• Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.

  Current medical research and opinion 20060801

• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  The Lancet. Oncology 20060801

• Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.

  American journal of clinical oncology 20060801

• Time to response: comparison of fulvestrant and oral endocrine agents.

  Clinical breast cancer 20060801

• Aromatase inhibitors and bone loss.

  Oncology (Williston Park, N.Y.) 20060801

• Use of aromatase inhibitors to increase final height.

  Molecular and cellular endocrinology 20060725

• Leuprolide acetate plus aromatase inhibition for male breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.

  Anti-cancer drugs 20060701

• Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.

  British journal of cancer 20060619

• Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

  British journal of cancer 20060605

• Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.

  Breast (Edinburgh, Scotland) 20060601

• Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.

  Journal of cancer research and clinical oncology 20060601

• Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.

  Journal of surgical oncology 20060601

• Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601

• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Anastrozole for breast cancer: recent advances and ongoing challenges.

  Expert review of anticancer therapy 20060601

• [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• Management of choroidal metastases from breast carcinomas using aromatase inhibitors.

  Current opinion in ophthalmology 20060601

• Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.

  Clinical breast cancer 20060601

• A durable complete remission between two isolated presentations of metastatic breast cancer, the second with intracardiac disease.

  Clinical breast cancer 20060601

• Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.

  International journal of clinical practice 20060601

• t(8;16) AML developed subsequent to breast cancer therapy.

  Hematology (Amsterdam, Netherlands) 20060601

• Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial.

  Cancer 20060515

• Effects of third-generation aromatase inhibitors on bone.

  European journal of cancer (Oxford, England : 1990) 20060501

• Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060501

• Primary hormone treatment in postmenopausal women with breast cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060501

• Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.

  British journal of cancer 20060410

• The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.

  European journal of endocrinology 20060401

• [Precocious puberty].

  Nihon rinsho. Japanese journal of clinical medicine 20060401

• [Clinical application of the gonadotropin--ovulation induction].

  Nihon rinsho. Japanese journal of clinical medicine 20060401

• The adjuvant endocrine treatment revolution: focus on anastrozole.

  Expert opinion on drug metabolism & toxicology 20060401

• A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

  British journal of cancer 20060327

• [Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].

  MMW Fortschritte der Medizin 20060323

• Regulation of sexual behaviour in male macaques by sex steroid modulation of the serotonergic system.

  Experimental physiology 20060301

• Fulvestrant ('Faslodex'): current and future role in breast cancer management.

  Critical reviews in oncology/hematology 20060301

• Aromatase inhibitors and breast cancer.

  Minerva endocrinologica 20060301

• [The evolving role of endocrine therapy for breast cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20060301

• Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.

  Endocrine-related cancer 20060301

• Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

  British journal of cancer 20060227

• Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060215

• Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation.

  Journal of medicinal chemistry 20060209

• The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.

  Human reproduction (Oxford, England) 20060201

• Neoadjuvant endocrine therapy in breast cancer.

  Breast (Edinburgh, Scotland) 20060201

• Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.

  Gynecologic oncology 20060201

• Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.

  European journal of endocrinology 20060201

• Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• Adjuvant endocrine therapy for postmenopausal women with early breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• [A case of postoperative pulmonary metastasis of breast cancer treated with docetaxel and cyclophosphamide therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.

  Breast (Edinburgh, Scotland) 20060201

• Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.

  Breast (Edinburgh, Scotland) 20060201

• Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.

  Journal of the National Cancer Institute 20060118

• Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom.

  British journal of cancer 20060116

• Hormonal therapy in epithelial ovarian cancer.

  Expert review of anticancer therapy 20060101

• Improvement in dermatomyositis rash associated with the use of antiestrogen medication.

  Archives of dermatology 20060101

• Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.

  Oncology 20060101

• Estrogen receptors as therapeutic targets in breast cancer.

  Current topics in medicinal chemistry 20060101

• Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

  BMC cancer 20060101

• Does survival increase in metastatic breast cancer with recently available anticancer drugs?

  Oncology research 20060101

• Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.

  BMC cancer 20060101

• [Fulvestrant: a new agent in endocrine treatment for breast cancer].

  Lijecnicki vjesnik 20060101

• Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).

  Tumori 20060101

• Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

  PharmacoEconomics 20060101

• Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• Estrogen receptors: role in breast cancer.

  Critical reviews in clinical laboratory sciences 20060101

• [A cost-effectiveness study of first-line hormone therapy in post-menopausal patients with metastatic breast cancer on neoadjuvant treatment].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Efficacy and tolerability of high dose 'ethinylestradiol' in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents.

  World journal of surgical oncology 20060101

• Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients.

  The International journal of biological markers 20060101

• Joint symptoms: a practical problem of anastrozole.

  Breast cancer (Tokyo, Japan) 20060101

• Cardiovascular safety profiles of aromatase inhibitors : a comparative review.

  Drug safety 20060101

• Choroidal metastasis in a patient with disseminated breast cancer: hormonal therapy-induced regression.

  The breast journal 20060101

• Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors.

  International seminars in surgical oncology : ISSO 20060101

• Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update.

  International seminars in surgical oncology : ISSO 20060101

• Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Bone safety of aromatase inhibitors versus tamoxifen.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• A fast liquid chromatographic/mass spectrometric screening method for the simultaneous detection of synthetic glucocorticoids, some stimulants, anti-oestrogen drugs and synthetic anabolic steroids.

  Rapid communications in mass spectrometry : RCM 20060101

• Appraising adjuvant aromatase inhibitor therapy.

  The oncologist 20060101

• Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.

  The oncologist 20060101

• The pathological findings of vasculitis simultaneously occurring with carcinoma, invasive breast carcinoma in a patient with Behçet's disease.

  Breast cancer (Tokyo, Japan) 20060101

• Adjuvant therapy for patients who have node-positive breast cancer.

  Advances in surgery 20060101

• Measuring proliferation in breast cancer: practicalities and applications.

  Breast cancer research : BCR 20060101

• [Current status of breast cancer chemoprevention].

  Revista da Associacao Medica Brasileira (1992) 20060101

• Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• Aromatase inhibitors in human lung cancer therapy.

  Cancer research 20051215

• Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20051201

• Adjuvant endocrine therapy in postmenopausal breast cancer patients.

  Breast (Edinburgh, Scotland) 20051201

• When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature.

  Breast (Edinburgh, Scotland) 20051201

• The biology of steroid hormones and endocrine treatment of breast cancer.

  Breast (Edinburgh, Scotland) 20051201

• Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.

  The Journal of steroid biochemistry and molecular biology 20051201

• Direct analysis of pharmaceutical drug formulations using ion mobility spectrometry/quadrupole-time-of-flight mass spectrometry combined with desorption electrospray ionization.

  Analytical chemistry 20051201

• Anal localization as first manifestation of metastatic ductal breast carcinoma.

  Techniques in coloproctology 20051201

• Future perspectives in the medical treatment of endometriosis.

  Obstetrical & gynecological survey 20051201

• Testotoxicosis: current viewpoint.

  Pediatric endocrinology reviews : PER 20051201

• Anastrozole called breast cancer 'lifesaver'. Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.

  Health news (Waltham, Mass.) 20051201

• Effects of decreased estradiol-17beta on the serum and anterior pituitary IGF-I system in pigs.

  The Journal of endocrinology 20051201

• [Advance and current status of exemestane and androstadienes in the treatment of breast cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051201

• Case 24-2005: a woman with estrogen-receptor-positive breast cancer.

  The New England journal of medicine 20051124

• New developments in the treatment of postmenopausal breast cancer.

  Trends in endocrinology and metabolism: TEM 20051101

• The use of aromatase inhibitors in adjuvant therapy for early breast cancer.

  Cancer chemotherapy and pharmacology 20051101

• Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

  Clinical therapeutics 20051101

• Anastrozole: a new gold standard of hormonal treatment for breast cancer?

  Women's health (London, England) 20051101

• Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051020

• Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.

  Cancer chemotherapy and pharmacology 20051001

• Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051001

• New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.

  Cancer 20051001

• A step too far?

  The Lancet. Oncology 20051001

• Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?

  Nature clinical practice. Oncology 20051001

• Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.

  Fertility and sterility 20051001

• Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.

  Clinical breast cancer 20051001

• Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.

  The journal of the British Menopause Society 20050901

• Promising switch to anastrozole for breast-cancer treatment.

  The Lancet. Oncology 20050901

• [Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• Radiotherapeutic prophylaxis of gynecomastia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.

  The New England journal of medicine 20050811

• Novel males' capacity to disrupt early pregnancy in mice (Mus musculus) is attenuated via a chronic reduction of males' urinary 17beta-estradiol.

  Psychoneuroendocrinology 20050801

• Selective oestrogen receptor modulators, aromatase inhibitors and the female breast.

  Current opinion in obstetrics & gynecology 20050801

• Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?

  European journal of cancer (Oxford, England : 1990) 20050801

• New approaches to reverse resistance to hormonal therapy in human breast cancer.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20050801

• Adjuvant aromatase inhibitors for breast cancer.

  Lancet (London, England) 20050801

• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

  Lancet (London, England) 20050801

• Anastrazole and oral contraceptives: a novel treatment for endometriosis.

  Fertility and sterility 20050801

• Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis.

  Fertility and sterility 20050801

• The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

  European journal of cancer (Oxford, England : 1990) 20050801

• Role of aromatase inhibitors in breast cancer.

  British journal of cancer 20050801

• Potential use of COX-2-aromatase inhibitor combinations in breast cancer.

  British journal of cancer 20050801

• Bone loss and the aromatase inhibitors.

  British journal of cancer 20050801

• The effects of aromatase inhibitors on lipids and thrombosis.

  British journal of cancer 20050801

• Sequencing of aromatase inhibitors.

  British journal of cancer 20050801

• The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.

  Clinical breast cancer 20050801

• [Aromatase inhibitors in the treatment of breast cancer: current status and some problems].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20050801

• Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20050801

• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

  Cancer 20050715

• The aromatase inhibitors in early breast cancer: who, when, and why?

  The Medical journal of Australia 20050704

• Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls.

  Fertility and sterility 20050701

• Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

  Cancer research 20050615

• A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.

  Cancer treatment reviews 20050601

• Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.

  The British journal of ophthalmology 20050601

• Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

  The Lancet. Oncology 20050601

• The aromatase inhibitor anastrozole is associated with favorable embryo development and implantation markers in mice ovarian stimulation cycles.

  Fertility and sterility 20050601

• Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.

  Expert opinion on pharmacotherapy 20050601

• Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.

  Prescrire international 20050601

• Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.

  Expert review of anticancer therapy 20050601

• Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20050601

• Breast cancer (metastatic).

  Clinical evidence 20050601

• Skeletal health in postmenopausal survivors of early breast cancer.

  International journal of cancer 20050510

• Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.

  British journal of cancer 20050509

• Aromatase inhibitors in the treatment of breast cancer.

  Endocrine reviews 20050501

• The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

  Cancer research 20050501

• Alternative to tamoxifen effective for preventing breast cancer recurrence.

  Mayo Clinic women's healthsource 20050501

• Vascular effects of aromatase inhibitors: data from clinical trials.

  The Journal of steroid biochemistry and molecular biology 20050501

• Aromatase inhibitors for therapy of advanced breast cancer.

  The Journal of steroid biochemistry and molecular biology 20050501

• Model systems: mechanisms involved in the loss of sensitivity to letrozole.

  The Journal of steroid biochemistry and molecular biology 20050501

• Mechanisms of resistance to aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20050501

• Aromatase inhibitors: cellular and molecular effects.

  The Journal of steroid biochemistry and molecular biology 20050501

• Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.

  The Journal of steroid biochemistry and molecular biology 20050501

• Surgical issues surrounding use of aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20050501

• Remission of macroglobulinemia during anastrozole treatment for breast cancer.

  The New England journal of medicine 20050421

• Aromatase inhibition: translation into a successful therapeutic approach.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• ATAC trial update.

  Lancet (London, England) 20050401

• ATAC trial update.

  Lancet (London, England) 20050401

• Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

  Molecular cancer research : MCR 20050401

• [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050401

• Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women.

  Clinical breast cancer 20050401

• Current and future perspectives on fulvestrant.

  Clinical breast cancer 20050401

• Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.

  Clinical breast cancer 20050401

• Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.

  Prescrire international 20050401

• Aromatase inhibitors for the treatment and prevention of breast cancer.

  Clinical breast cancer 20050401

• Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols: synthesis and inhibition of P450 aromatase.

  Journal of enzyme inhibition and medicinal chemistry 20050401

• Anastrozole.

  Drugs of today (Barcelona, Spain : 1998) 20050401

• Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.

  British journal of cancer 20050328

• Aromatase inhibitors in advanced breast cancer: there are efficacy differences.

  British journal of cancer 20050328

• [Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].

  MMW Fortschritte der Medizin 20050310

• [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].

  MMW Fortschritte der Medizin 20050310

• Clinical applications of hormonal therapy in ovarian cancer.

  Current treatment options in oncology 20050301

• Innovations in antineoplastic therapy.

  The Nursing clinics of North America 20050301

• [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Zoledronic acid prevents cancer treatment-induced bone loss.

  Oncology (Williston Park, N.Y.) 20050301

• Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.

  European journal of obstetrics, gynecology, and reproductive biology 20050201

• Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.

  Clinical endocrinology 20050201

• Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Endocrine treatment options for advanced breast cancer--the role of fulvestrant.

  European journal of cancer (Oxford, England : 1990) 20050201

• The choice of systemic adjuvant therapy in receptor-positive early breast cancer.

  European journal of cancer (Oxford, England : 1990) 20050201

• Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

  Cancer treatment reviews 20050201

• Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050201

• Evaluating bone mass and bone quality in patients with breast cancer.

  Clinical breast cancer 20050201

• Are aromatase inhibitors superior to antiestrogens?

  The Journal of steroid biochemistry and molecular biology 20050201

• Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.

  The Journal of steroid biochemistry and molecular biology 20050201

• Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.

  British journal of cancer 20050131

• The role of aromatization in testosterone supplementation: effects on cognition in older men.

  Neurology 20050125

• Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation.

  The Cochrane database of systematic reviews 20050125

• Anastrozole data show continued delay in relapse, but no clear survival advantage.

  Journal of the National Cancer Institute 20050119

• Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Therapeutic observations in MCF-7 aromatase xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Prevention of hormone-related cancers: breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050110

• Short-term aromatase-enzyme blockade unmasks impaired feedback adaptations in luteinizing hormone and testosterone secretion in older men.

  The Journal of clinical endocrinology and metabolism 20050101

• Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.

  The Journal of clinical endocrinology and metabolism 20050101

• The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.

  Human reproduction (Oxford, England) 20050101

• How rapidly do oncologists respond to clinical trial data?

  The oncologist 20050101

• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  Lancet (London, England) 20050101

• Aromatase 2004, Edinburgh, UK, 6-8 September 2004.

  Breast cancer research : BCR 20050101

• Deficits in plasma oestradiol measurement in studies and management of breast cancer.

  Breast cancer research : BCR 20050101

• Interactions between antiretrovirals and antineoplastic drug therapy.

  Clinical pharmacokinetics 20050101

• Endometriosis: new genetic approaches and therapy.

  Annual review of medicine 20050101

• Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.

  Prostate cancer and prostatic diseases 20050101

• Total mastectomy under local anesthesia: the tumescent technique.

  The breast journal 20050101

• Clinical trial update: National Cancer Institute of Canada.

  Breast cancer research : BCR 20050101

• Optimizing the treatment of metastatic breast cancer.

  Breast cancer research and treatment 20050101

• Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.

  Acta oncologica (Stockholm, Sweden) 20050101

• Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.

  Cancer investigation 20050101

• Aromatase inhibitors in the treatment of early and advanced breast cancer.

  Acta oncologica (Stockholm, Sweden) 20050101

• Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?

  Breast cancer research : BCR 20050101

• Mechanisms of ensemble failure of the male gonadal axis in aging.

  Journal of endocrinological investigation 20050101

• Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.

  Oncology 20050101

• Early stopping of clinical trials.

  Breast cancer research : BCR 20050101

• Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.

  Breast cancer research : BCR 20050101

• The future of fulvestrant ('Faslodex').

  Cancer treatment reviews 20050101

• The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.

  Reproductive biology and endocrinology : RB&E 20050101

• Life following aromatase inhibitors--where now for endocrine sequencing?

  Breast cancer research and treatment 20050101

• Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.

  Breast cancer research : BCR 20050101

• Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.

  MedGenMed : Medscape general medicine 20050101

• Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.

  Oncology 20050101

• Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.

  Breast cancer research : BCR 20050101

• Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).

  Breast disease 20050101

• Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.

  Breast disease 20050101

• State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.

  German medical science : GMS e-journal 20050101

• Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.

  Life sciences 20041231

• Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.

  Cancer treatment reviews 20041201

• Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041201

• Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.

  Expert opinion on pharmacotherapy 20041201

• Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.

  European journal of cancer (Oxford, England : 1990) 20041201

• The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.

  European journal of cancer (Oxford, England : 1990) 20041201

• Neoadjuvant endocrine therapy in primary breast cancer.

  Clinical breast cancer 20041201

• Are all aromatase inhibitors the same? A review of the current evidence.

  Breast (Edinburgh, Scotland) 20041201

• Long-term implications of bone loss in breast cancer.

  Breast (Edinburgh, Scotland) 20041201

• A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers.

  Fertility and sterility 20041201

• Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.

  American journal of obstetrics and gynecology 20041201

• Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.

  Endocrine-related cancer 20041201

• [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].

  Bulletin du cancer 20041201

• Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.

  Clinical journal of oncology nursing 20041201

• An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys.

  Journal of pediatric endocrinology & metabolism : JPEM 20041201

• Aromatase inhibitors and breast cancer: time for a change?

  International journal of clinical practice 20041201

• Aromatase inhibitors in advanced breast cancer.

  Seminars in oncology 20041201

• Aromatase inhibitors in early breast cancer therapy.

  Seminars in oncology 20041201

• Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.

  Seminars in oncology 20041201

• [Aromatase inhibitors in adjuvant setting in breast cancer].

  Bulletin du cancer 20041201

• Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.

  The Journal of biological chemistry 20041112

• Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.

  The international journal of biochemistry & cell biology 20041101

• Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.

  British journal of cancer 20041101

• Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.

  Breast cancer research and treatment 20041101

• [Anastrozole-resistant breast cancer responsive to exemestane--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• Aromatase inhibitors: a new paradigm in breast cancer treatment.

  Current medicinal chemistry. Anti-cancer agents 20041101

• Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.

  Bulletin of experimental biology and medicine 20041101

• Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors.

  Bioorganic & medicinal chemistry letters 20041018

• Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients.

  British journal of cancer 20041004

• [Ulcus terebrans. Therapy options and their limits].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20041001

• The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.

  Cancer 20041001

• Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20041001

• [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [Postoperative hormone (endocrine) therapy in endometrial carcinoma].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.

  Current opinion in investigational drugs (London, England : 2000) 20041001

• [Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].

  Ginecologia y obstetricia de Mexico 20041001

• Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.

  Cancer 20040915

• Current developments in hormonal therapy of breast cancer.

  Clinical breast cancer 20040901

• The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.

  Clinical breast cancer 20040901

• Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.

  Clinical breast cancer 20040901

• Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?

  Clinical breast cancer 20040901

• Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.

  Gynecologic oncology 20040901

• Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.

  The Journal of clinical endocrinology and metabolism 20040901

• A review of adjuvant hormonal therapy in breast cancer.

  Endocrine-related cancer 20040901

• Shifting paradigms in hormonal therapy for breast cancer.

  Cancer biology & therapy 20040901

• Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.

  Anti-cancer drugs 20040901

• Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.

  Clinical therapeutics 20040901

• Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.

  Drugs of today (Barcelona, Spain : 1998) 20040901

• Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.

  Cancer 20040815

• The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.

  Cancer 20040801

• An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.

  European journal of cancer (Oxford, England : 1990) 20040801

• Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.

  Gynecologic oncology 20040801

• Beating breast cancer.

  Nursing standard (Royal College of Nursing (Great Britain) : 1987) 20040801

• Role of aromatase inhibitors in the treatment of breast cancer.

  Clinical therapeutics 20040801

• Cost-effectiveness of letrozole in the treatment of advanced breast cancer.

  Expert review of pharmacoeconomics & outcomes research 20040801

• Cost of managing women presenting with stage IV breast cancer in the United Kingdom.

  British journal of cancer 20040705

• Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.

  The Journal of clinical endocrinology and metabolism 20040701

• [Tamoxifen-induced severe hypertriglyceridemia--report of 3 cases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• The curability of breast cancer and the treatment of advanced disease.

  European journal of nuclear medicine and molecular imaging 20040601

• Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.

  Breast cancer research and treatment 20040601

• Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome.

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20040601

• Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?

  Cancer treatment reviews 20040601

• Aromatase inhibitors in breast cancer.

  Endocrine-related cancer 20040601

• [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20040601

• [Aromatase inhibitors in the adjuvant therapy of breast carcinomas].

  Therapeutische Umschau. Revue therapeutique 20040601

• Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?

  British journal of cancer 20040504

• Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer.

  Cancer treatment reviews 20040501

• Comment on 'Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results' by J.-M. Nabholtz et al.

  European journal of cancer (Oxford, England : 1990) 20040501

• Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor.

  Fertility and sterility 20040501

• The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20040501

• NCCN Guideline update: Breast Cancer Version 1.2004.

  Journal of the National Comprehensive Cancer Network : JNCCN 20040501

• 200 Sentinel lymph node biopsies without axillary lymph node dissection -- no axillary recurrences after a 3-year follow-up.

  British journal of cancer 20040419

• Adjuvant use of anastrozole in breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.

  Journal of the American Geriatrics Society 20040401

• [Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results].

  Gynakologisch-geburtshilfliche Rundschau 20040401

• Effect of estrogen deprivation on follicle/oocyte maturation and embryo development in mice.

  Chinese medical journal 20040401

• In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.

  European journal of cancer (Oxford, England : 1990) 20040401

• Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

  Journal of the National Cancer Institute 20040317

• [The uterine sarcoma, a new risk identified for tamoxifen].

  Presse medicale (Paris, France : 1983) 20040313

• The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

  Best practice & research. Clinical endocrinology & metabolism 20040301

• Aromatase inhibitors for chemoprevention.

  Best practice & research. Clinical endocrinology & metabolism 20040301

• Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.

  The Journal of clinical endocrinology and metabolism 20040301

• Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

  British journal of cancer 20040301

• Fulvestrant: pharmacokinetics and pharmacology.

  British journal of cancer 20040301

• Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.

  British journal of cancer 20040301

• Fulvestrant and the sequential endocrine cascade for advanced breast cancer.

  British journal of cancer 20040301

• Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

  British journal of cancer 20040209

• Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.

  Journal of surgical oncology 20040201

• Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.

  International journal of impotence research 20040201

• Anastrozole (Arimidex).

  Clinical journal of oncology nursing 20040201

• [Controversies in endocrine therapy for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040201

• Progress in chemoprevention of breast cancer.

  Critical reviews in oncology/hematology 20040201

• Aromatase inhibitors: new endocrine treatment of breast cancer.

  Seminars in reproductive medicine 20040201

• Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.

  Acta radiologica (Stockholm, Sweden : 1987) 20040201

• First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

  British journal of cancer 20040112

• Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.

  British journal of cancer 20040112

• Spreading the word, but not too thinly.

  Lancet (London, England) 20040110

• Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.

  Breast cancer research : BCR 20040101

• 8th Nottingham International Breast Cancer Conference, Nottingham, UK, 16-19 September 2003.

  Breast cancer research : BCR 20040101

• The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.

  Human reproduction (Oxford, England) 20040101

• Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool.

  Archives of surgery (Chicago, Ill. : 1960) 20040101

• Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Prevention strategies with aromatase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.

  Psycho-oncology 20040101

• [Neoadjuvant endocrine therapy for breast cancer: an overview].

  Bulletin du cancer 20040101

• 26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3-6 December 2003: update on clinical research.

  Breast cancer research : BCR 20040101

• Hormonal therapy in early and advanced breast cancer.

  The breast journal 20040101

• Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

  Drugs 20040101

• Aromatase inhibitors for breast cancer in postmenopausal women.

  The oncologist 20040101

• The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.

  The breast journal 20040101

• Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer.

  Anticancer research 20040101

• Letrozole: a review of its use in postmenopausal women with breast cancer.

  Drugs 20040101

• Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.

  Clinical pharmacokinetics 20040101

• [The ATAC study on adjuvants in breast cancer].

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20040101

• [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20040101

• Breast cancer research and the European Union Clinical Trials Directive.

  Breast cancer research : BCR 20040101

• Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.

  Breast cancer research : BCR 20040101

• Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group.

  Breast cancer research : BCR 20040101

• Tamoxifen--what next?

  The oncologist 20040101

• Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole.

  Hormone research 20040101

• Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial.

  Cancer control : journal of the Moffitt Cancer Center 20040101

• Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.

  Breast cancer research : BCR 20040101

• Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20040101

• Biomarker investigations from the ATAC trial: the role of TA01.

  Breast cancer research and treatment 20040101

• The scientific value of preoperative studies and how they can be used.

  Breast cancer research and treatment 20040101

• Designing the future shape of breast cancer diagnosis, prognosis and treatment.

  Breast cancer research and treatment 20040101

• Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.

  The American journal of hospice & palliative care 20040101

• [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer].

  Tumori 20040101

• [New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].

  MMW Fortschritte der Medizin 20031211

• [Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].

  MMW Fortschritte der Medizin 20031211

• New findings about endocrine therapy for breast cancer.

  Breast (Edinburgh, Scotland) 20031201

• Pharmacological prevention of breast cancer: quo vadis?

  Breast (Edinburgh, Scotland) 20031201

• The best use of adjuvant endocrine treatments.

  Breast (Edinburgh, Scotland) 20031201

• The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.

  BJOG : an international journal of obstetrics and gynaecology 20031201

• Phase II trial of anastrozole in women with asymptomatic müllerian cancer.

  Gynecologic oncology 20031201

• A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.

  Breast cancer research and treatment 20031201

• New developments in endocrine therapy: role of adjuvant therapy for early breast cancer.

  Cancer nursing 20031201

• Clinical trials update: Medical management of advanced breast cancer.

  Cancer nursing 20031201

• Breast cancer (metastatic).

  Clinical evidence 20031201

• Endogenous estrogens influence endothelial function in young men.

  Circulation research 20031128

• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.

  British journal of cancer 20031117

• Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.

  Cancer research 20031115

• Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20031101

• Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.

  European journal of cancer (Oxford, England : 1990) 20031101

• An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.

  European journal of cancer (Oxford, England : 1990) 20031101

• Adjuvant aromatase inhibitors: are we there yet?

  Cancer 20031101

• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  Cancer 20031101

• ATAC trial did not report interim results.

  BMJ (Clinical research ed.) 20031101

• Aromatase inhibitors in breast cancer therapy.

  Clinical breast cancer 20031101

• Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.

  Clinical therapeutics 20031101

• Doctors test drug to prevent cancer in high risk women.

  BMJ (Clinical research ed.) 20031004

• Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20031001

• Fulvestrant in postmenopausal women with advanced breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.

  Seminars in oncology 20031001

• Role of anastrozole in adjuvant therapy for postmenopausal patients.

  Seminars in oncology 20031001

• The pharmacology of letrozole.

  The Journal of steroid biochemistry and molecular biology 20031001

• An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.

  The Canadian journal of urology 20031001

• Anastrozole for ductal carcinoma in situ.

  Lancet (London, England) 20030906

• [Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].

  Zentralblatt fur Gynakologie 20030901

• Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.

  The Journal of steroid biochemistry and molecular biology 20030901

• Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.

  The Journal of steroid biochemistry and molecular biology 20030901

• Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.

  The Journal of steroid biochemistry and molecular biology 20030901

• Aromatase inhibitors as adjuvant therapies in patients with breast cancer.

  The Journal of steroid biochemistry and molecular biology 20030901

• Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.

  The Journal of steroid biochemistry and molecular biology 20030901

• Advanced breast cancer updates on anastrozole versus tamoxifen.

  The Journal of steroid biochemistry and molecular biology 20030901

• 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.

  The Journal of steroid biochemistry and molecular biology 20030901

• The effects of hormone therapy on cognition in breast cancer.

  The Journal of steroid biochemistry and molecular biology 20030901

• An integrated view of aromatase and its inhibition.

  The Journal of steroid biochemistry and molecular biology 20030901

• Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.

  The Journal of steroid biochemistry and molecular biology 20030901

• Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20030901

• Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features.

  British journal of cancer 20030818

• The current status of aromatase inhibitors in the management of breast cancer.

  The Surgical clinics of North America 20030801

• Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.

  European journal of cancer (Oxford, England : 1990) 20030801

• A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.

  American journal of clinical oncology 20030801

• Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.

  American journal of clinical oncology 20030801

• Emerging role of aromatase inhibitors in the adjuvant setting.

  American journal of clinical oncology 20030801

• Examining quality of life issues in relation to endocrine therapy for breast cancer.

  American journal of clinical oncology 20030801

• Progress in systemic adjuvant therapy of early-stage breast cancer.

  International journal of clinical oncology 20030801

• Should aromatase inhibitors replace tamoxifen?

  Drug and therapeutics bulletin 20030801

• Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.

  Seminars in oncology 20030801

• Aromatase inhibitor development and hormone therapy: a perspective.

  Seminars in oncology 20030801

• Pharmacokinetics of third-generation aromatase inhibitors.

  Seminars in oncology 20030801

• The role of aromatase inhibitors in the treatment of metastatic breast cancer.

  Seminars in oncology 20030801

• Aromatase inhibitors in early breast cancer treatment.

  Seminars in oncology 20030801

• Hormonal therapy: introduction.

  Breast (Edinburgh, Scotland) 20030801

• Challenges in the endocrine management of breast cancer.

  Breast (Edinburgh, Scotland) 20030801

• Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.

  British journal of cancer 20030721

• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.

  Cancer 20030715

• Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030701

• Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?

  The Journal of steroid biochemistry and molecular biology 20030701

• ATAC trial: reporting interim results is not helpful.

  BMJ (Clinical research ed.) 20030614

• [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].

  MMW Fortschritte der Medizin 20030612

• Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?

  Journal of the National Cancer Institute 20030604

• Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.

  European journal of cancer (Oxford, England : 1990) 20030601

• Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.

  American journal of clinical oncology 20030601

• Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.

  American journal of clinical oncology 20030601

• Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation.

  Southern medical journal 20030601

• Anastrozole as a preventive agent in breast cancer.

  Lancet (London, England) 20030531

• Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.

  The New England journal of medicine 20030508

• Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?

  International journal of oncology 20030501

• The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression.

  American journal of surgery 20030501

• Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.

  Oncology (Williston Park, N.Y.) 20030501

• Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.

  Breast cancer research and treatment 20030501

• The role of aromatase inhibitors in early breast cancer.

  Current treatment options in oncology 20030401

• Adjuvant systemic therapy of early stage breast cancer.

  Current treatment options in oncology 20030401

• Update on the current use of hormonals as therapy in advanced breast cancer.

  Anti-cancer drugs 20030401

• [Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].

  Revista clinica espanola 20030401

• Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.

  Expert review of anticancer therapy 20030401

• 21. The adjuvant treatment of breast cancer.

  International journal of clinical practice 20030401

• Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

  Clinical breast cancer 20030401

• The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.

  Journal of the National Comprehensive Cancer Network : JNCCN 20030401

• Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.

  The Medical letter on drugs and therapeutics 20030317

• Is tamoxifen the Rosetta stone for breast cancer?

  Journal of the National Cancer Institute 20030305

• The therapeutic potential of aromatase inhibitors.

  Expert opinion on investigational drugs 20030301

• Aromatase inhibitors as adjuvant therapy in breast cancer.

  Oncology (Williston Park, N.Y.) 20030301

• Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.

  British journal of cancer 20030224

• Update on clinical role of tamoxifen.

  Current opinion in obstetrics & gynecology 20030201

• Current and future status of adjuvant therapy for breast cancer.

  Cancer 20030201

• Update on ATAC.

  European journal of cancer (Oxford, England : 1990) 20030201

• Breast cancer prevention.

  The British journal of general practice : the journal of the Royal College of General Practitioners 20030201

• [Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].

  MMW Fortschritte der Medizin 20030123

• Differential effects of androgens and estrogens on bone turnover in normal men.

  The Journal of clinical endocrinology and metabolism 20030101

• Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• Clinical differences among the aromatase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• Adjuvant endocrine therapy in postmenopausal breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on clinical research.

  Breast cancer research : BCR 20030101

• Treatment of breast cancer in countries with limited resources.

  The breast journal 20030101

• Current status of endocrine therapy for breast cancer.

  Breast cancer (Tokyo, Japan) 20030101

• Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.

  Breast cancer (Tokyo, Japan) 20030101

• New options in the prevention and treatment of breast carcinoma.

  Journal of the Medical Association of Georgia 20030101

• A roundtable discussion of aromatase inhibitors as therapy for breast cancer.

  The breast journal 20030101

• Hormonal therapy in postmenopausal women with breast cancer.

  Oncology 20030101

• Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.

  The oncologist 20030101

• Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20030101

• Safety issues surrounding the use of aromatase inhibitors in breast cancer.

  Expert opinion on drug safety 20030101

• Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).

  Breast cancer research : BCR 20030101

• 5th Milan Breast Cancer Conference, Milan, Italy, 11-13 June 2003.

  Breast cancer research : BCR 20030101

• [Perspectives for the hormonal therapy of breast cancer].

  Magyar onkologia 20030101

• [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis].

  Zentralblatt fur Gynakologie 20030101

• Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

  Breast cancer research and treatment 20030101

• Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

  Breast cancer research and treatment 20030101

• Future directions in the endocrine therapy of breast cancer.

  Breast cancer research and treatment 20030101

• Introducing a new section to Breast Cancer Research: endocrinology and hormone therapy.

  Breast cancer research : BCR 20030101

• Focus on anastrozole and breast cancer.

  Current medical research and opinion 20030101

• NCCN breast cancer clinical practice guidelines in oncology: an update.

  Journal of the National Comprehensive Cancer Network : JNCCN 20030101

• Questions about anastrozole for early breast cancer.

  Lancet (London, England) 20021207

• Questions about anastrozole for early breast cancer.

  Lancet (London, England) 20021207

• A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.

  British journal of cancer 20021202

• Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.

  Cancer 20021201

• New treatment option for postmenopausal women with early breast cancer.

  Expert review of anticancer therapy 20021201

• Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.

  Expert review of anticancer therapy 20021201

• [A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021201

• Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.

  Endocrine-related cancer 20021201

• From the Food and Drug Administration.

  JAMA 20021106

• Expression and purification of a recombinant form of human aromatase from Escherichia coli.

  Biochemical pharmacology 20021101

• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.

  Cancer 20021101

• Anastrozole versus progestins/tamoxifen.

  European journal of cancer (Oxford, England : 1990) 20021101

• Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

  European journal of cancer (Oxford, England : 1990) 20021101

• Selective oestrogen receptor downregulator.

  European journal of cancer (Oxford, England : 1990) 20021101

• Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.

  European journal of cancer (Oxford, England : 1990) 20021101

• Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.

  Breast cancer research and treatment 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.

  British journal of cancer 20021021

• New generation aromatase inhibitors--from the advanced to the adjuvant setting.

  Breast cancer research and treatment 20021001

• A new estrogen receptor antagonist--an overview of available data.

  Breast cancer research and treatment 20021001

• Sequencing of endocrine therapies in breast cancer--integration of recent data.

  Breast cancer research and treatment 20021001

• The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

  The Journal of clinical endocrinology and metabolism 20021001

• The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.

  European journal of cancer (Oxford, England : 1990) 20021001

• The evolving role of aromatase inhibitors in breast cancer.

  International journal of clinical oncology 20021001

• Invasive lobular carcinoma of the breast presenting successively with colonic and gastric metastases.

  International journal of clinical practice 20021001

• [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].

  MMW Fortschritte der Medizin 20020919

• Anastrozole in the management of breast cancer.

  Expert opinion on pharmacotherapy 20020901

• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020901

• Rapid determination of anastrozole in plasma by gas chromatography with electron capture detection and its application to an oral pharmacokinetic study in healthy volunteers.

  Biomedical chromatography : BMC 20020901

• [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020901

• Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020815

• Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020815

• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020801

• Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.

  British journal of cancer 20020729

• Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020701

• Stick with tried-and-true breast cancer treatment.

  Health news (Waltham, Mass.) 20020701

• New alternative to tamoxifen.

  Harvard women's health watch 20020701

• Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020701

• Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.

  Lancet (London, England) 20020622

• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  Lancet (London, England) 20020622

• Aromatase inhibition for ovarian stimulation: future avenues for infertility management.

  Current opinion in obstetrics & gynecology 20020601

• Efficacy of anastrozole in male breast cancer.

  American journal of clinical oncology 20020601

• [Antiestrogen therapy in the treatment of breast neoplasms].

  Minerva ginecologica 20020601

• Letrozole for the management of breast cancer.

  Expert review of anticancer therapy 20020601

• Recent advances in aromatase inhibitor therapy for breast cancer.

  Seminars in oncology 20020601

• Concept evaluation: an assay for receptor-mediated and biochemical antiestrogens using pubertal rats.

  Regulatory toxicology and pharmacology : RTP 20020601

• A better medication for treating breast cancer?

  The Johns Hopkins medical letter health after 50 20020501

• Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.

  Bone marrow transplantation 20020501

• Effects of aromatase inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture.

  Molecular reproduction and development 20020401

• New breast cancer drugs expand treatment options.

  Harvard women's health watch 20020401

• Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.

  The Journal of steroid biochemistry and molecular biology 20020401

• Antiaromatase agents: evolving role in adjuvant therapy.

  Clinical breast cancer 20020401

• [The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].

  Minerva ginecologica 20020401

• The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant.

  Cancer nursing 20020401

• Existing and emerging endocrine therapies for breast cancer.

  Cancer nursing 20020401

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020401

• Fulvestrant (Faslodex): current status in the therapy of breast cancer.

  Expert review of anticancer therapy 20020401

• Aromatase inhibitors in breast cancer therapy.

  Expert review of anticancer therapy 20020401

• Detection of aromatase inhibitors in vitro using rat ovary microsomes.

  Toxicology letters 20020324

• Aromatase inhibitors in breast cancer.

  Trends in endocrinology and metabolism: TEM 20020301

• Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.

  The Israel Medical Association journal : IMAJ 20020301

• Aromatase inhibitors for male infertility.

  The Journal of urology 20020201

• Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020201

• Fulvestrant.

  Expert opinion on investigational drugs 20020201

• [Aromatase inhibitors of the 3rd generation. What can the 'pill against breast cancer' really do?].

  MMW Fortschritte der Medizin 20020131

• World's largest breast cancer treatment trial supports anastrozole use.

  Oncology (Williston Park, N.Y.) 20020101

• Hormones 'R' us.

  Clinical breast cancer 20020101

• Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer.

  Clinical therapeutics 20020101

• Aromatase inhibitors continue their ATAC on tamoxifen.

  Trends in molecular medicine 20020101

• Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.

  Drugs 20020101

• Anti-aromatase agents in the treatment and prevention of breast cancer.

  Cancer control : journal of the Moffitt Cancer Center 20020101

• Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.

  Cancer control : journal of the Moffitt Cancer Center 20020101

• Recent advances in breast cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001).

  Current medical research and opinion 20020101

• Estrogen as therapy for breast cancer.

  Breast cancer research : BCR 20020101

• Finding the needle in the haystack: why high-throughput screening is good for your health.

  Breast cancer research : BCR 20020101

• The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.

  Clinical therapeutics 20020101

• Evolving uses of hormonal agents for breast cancer therapy.

  Clinical therapeutics 20020101

• Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.

  Clinical therapeutics 20020101

• Efficacy and economics of hormonal therapies for advanced breast cancer.

  Drugs & aging 20020101

• McCune-Albright syndrome--the German experience.

  Journal of pediatric endocrinology & metabolism : JPEM 20020101

• Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.

  Journal of pediatric endocrinology & metabolism : JPEM 20020101

• British Cancer Research Meeting, 30 June-3 July 2002, Glasgow.

  Breast cancer research : BCR 20020101

• Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.

  Breast cancer research : BCR 20020101

• Anastrozole: in early breast cancer.

  Drugs 20020101

• Breast cancer chemoprevention--an update.

  Current medical research and opinion 20020101

• Current role of endocrine therapy in the management of breast cancer.

  Breast cancer (Tokyo, Japan) 20020101

• Has tamoxifen had its day?

  Breast cancer research : BCR 20020101

• A new day dawns: women without oestrogen or is a balance best?

  Breast cancer research : BCR 20020101

• Advances in breast oncology: the 2002 ASCO meeting.

  Current medical research and opinion 20020101

• FDA drug approval summaries: fulvestrant.

  The oncologist 20020101

• Aromatase inhibitors in breast cancer: an update.

  Cancer control : journal of the Moffitt Cancer Center 20020101

• Interactions of antioestrogens and aromatase inhibitors.

  Forum (Genoa, Italy) 20020101

• HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

  Cancer research 20011201

• High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.

  Surgery 20011201

• Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20011201

• Local endocrine effects of aromatase inhibitors within the breast.

  The Journal of steroid biochemistry and molecular biology 20011201

• Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.

  The Journal of steroid biochemistry and molecular biology 20011201

• A summary of second-line randomized studies of aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20011201

• Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy.

  The Journal of steroid biochemistry and molecular biology 20011201

• Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.

  The Journal of steroid biochemistry and molecular biology 20011201

• Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

  The Journal of steroid biochemistry and molecular biology 20011201

• The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Are differences in the available aromatase inhibitors and inactivators significant?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Preliminary experience with pure antiestrogens.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Preliminary data from ongoing adjuvant aromatase inhibitor trials.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Future use of selective estrogen receptor modulators and aromatase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Promising results for Arimidex and Femara.

  Expert review of anticancer therapy 20011201

• Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.

  Cancer 20011101

• Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

  Annals of oncology : official journal of the European Society for Medical Oncology 20011101

• ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.

  British journal of cancer 20011101

• A vision for the future?

  British journal of cancer 20011101

• Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?

  British journal of cancer 20011101

• Aromatase inhibitors and inactivators in breast cancer.

  BMJ (Clinical research ed.) 20011020

• Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma.

  Cancer 20011015

• Role of anti-aromatase agents in postmenopausal advanced breast cancer.

  Cancer chemotherapy and pharmacology 20011001

• Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010901

• Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.

  British journal of cancer 20010801

• Nonsteroidal and steroidal aromatase inhibitors in breast cancer.

  Oncology (Williston Park, N.Y.) 20010801

• Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.

  Prescrire international 20010801

• Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.

  Expert review of anticancer therapy 20010801

• [Developments of hormonal agents for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010701

• [Endocrine therapy for advanced or recurrent breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010701

• Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men.

  The Journal of clinical endocrinology and metabolism 20010601

• The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men.

  The Journal of clinical endocrinology and metabolism 20010601

• Endocrine therapy in the treatment of metastatic breast cancer.

  Seminars in oncology 20010601

• Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.

  Prescrire international 20010601

• Pharmacokinetics of anastrozole in Chinese male volunteers.

  Acta pharmacologica Sinica 20010601

• Aromatase inhibitors and arthralgia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515

• Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501

• Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501

• Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501

• Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501

• Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501

• Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.

  Oncology (Williston Park, N.Y.) 20010501

• [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20010501

• The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers.

  British journal of clinical pharmacology 20010501

• Estrogenic upregulation of DNA polymerase beta in oocytes of preovulatory ovine follicles.

  Molecular reproduction and development 20010401

• [Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010401

• Importance of local aromatase activity in hormone-dependent breast cancer: a review.

  Breast (Edinburgh, Scotland) 20010401

• Aromatase inhibitors in the treatment and prevention of breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201

• The uterotrophic activity of nonylphenol in the rat is not mediated by aromatase enzyme induction.

  Toxicology letters 20010103

• Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.

  The oncologist 20010101

• Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion.

  The Journal of clinical endocrinology and metabolism 20010101

• [Endometriosis and aromatase inhibitor].

  Nihon rinsho. Japanese journal of clinical medicine 20010101

• Breast cancer chemoprevention: beyond tamoxifen.

  Breast cancer research : BCR 20010101

• The Twenty-third Annual San Antonio Breast Cancer Symposium.

  Current medical research and opinion 20010101

• Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000.

  Breast cancer research : BCR 20010101

• [Modern approaches to hormone therapy of breast cancer as a reflection of pathogenesis of the disease].

  Voprosy onkologii 20010101

• Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20010101

• Fulvestrant.

  Drugs 20010101

• [Evolvement of hormone therapy for breast cancer. Florence, March 14, 2001].

  Tumori 20010101

• Aromatase, aromatase inhibitors, and breast cancer.

  American journal of therapeutics 20010101

• New combinations with Herceptin in metastatic breast cancer.

  Oncology 20010101

• Third-generation aromatase inhibitors in the treatment of advanced breast cancer.

  Breast cancer (Tokyo, Japan) 20010101

• Aromatase and aromatase inhibitors.

  Breast cancer (Tokyo, Japan) 20010101

• Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.

  Cancer control : journal of the Moffitt Cancer Center 20010101

• Aromatase inhibitors.

  Current medical research and opinion 20010101

• Pure antiestrogens and breast cancer.

  Current medical research and opinion 20010101

• Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility.

  The Journal of endocrinology 20000201

• A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 19991001

• Arimidex: a potent and selective fourth-generation aromatase inhibitor.

  Breast cancer research and treatment 19940101

• Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.

  The Journal of steroid biochemistry and molecular biology 19901220